Crystal form of BTK inhibitor
Patent Information
- Application Number
- JP2024145192
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2019-05-23
- Filing Date
- 2024-08-27
- Publication Date
- 2024-11-26
AI Technical Summary
を提供することになる。
Smart Images

Figure 2024164208000018 
Figure 2024164208000019 
Figure 2024164208000020
Abstract
Description
[Technical field]
[0001] FIELD OF THEINVENTION The present disclosure relates to N-(3-(6-amino-5-(2-(N-methylacrylamide)ethoxy) Pyrimidin-4-yl)-5-fluoro-2-methylphenyl)-4-cyclopropane The present disclosure also relates to a crystalline form of 2-fluoro-benzamide. Pharmaceutical compositions and methods for obtaining such crystalline forms, typically Bruton's tyrosine Methods of using such crystalline forms in the treatment of diseases and disorders ameliorated by the inhibition of kinases Such diseases and disorders include inflammatory and autoimmune disorders, and Inflammation of the lungs and airways may be included.
[0002] background Polymorphism refers to the existence of more than one crystalline form of a substance.
[0003] The solid form of a particular drug's active pharmaceutical ingredient (API) may vary depending on the ease of preparation of the drug, its hygroscopicity, , stability, solubility, storage stability, ease of formulation, dissolution rate in gastrointestinal fluids, and in vivo Crystal form is often an important determinant of the bioavailability of a drug. Substances crystallize in different lattice arrangements, resulting in different thermodynamic properties that are specific to particular crystalline forms. Crystal forms also occur when different hydrates of the same compound provide stability and stability. In determining which form is preferred, a number of properties of the forms may be compared. The preferred form is selected based on a number of physical property variables, such as ease of preparation, stability, etc. It is quite possible that in situations where a particular aspect is important, a certain form may be preferred. In other situations, higher dissolution rates and / or better bioavailability may be achieved. Therefore, another form may be preferred.
[0004] This ability of a chemical to crystallize into multiple crystalline forms therefore plays a key role in determining the shelf life, dissolution rate, and / or solubility of a drug. It can have a significant impact on the dissolution, formulation and processing properties of the drug. The use of this drug may be affected by polymorphism of the molecule. Different polymorphs can affect The uptake rates of the agonist may be different, resulting in less than desirable biological activity. In extreme cases, the undesired polymorphism may even be toxic. The occurrence of unknown crystal morphology during manufacturing can have a major impact.
[0005] Whether a particular compound or salt of a compound forms polymorphs and whether any such polymorphs are therapeutically effective whether or not the type is suitable for commercial use in pharmaceutical compositions, or which type has such desirable properties. However, in certain cases, it is not possible to predict whether Understanding which crystalline forms are possible allows researchers to improve solubility, formulation properties, processing, and In the early stages of development of a new drug, the desired properties of the compound, such as drug activity, drug duration, etc., can be maximized. Understanding these factors could ultimately lead to more active, more stable, or less expensive drugs. You can taste it.
[0006] Therefore, N-(3-(6-amino-5-(2-(N-methylacrylamide)ethoxy )pyrimidin-4-yl)-5-fluoro-2-methylphenyl)-4-cyclopropyl - To enable the reliable production of safe and effective medicines containing 2-fluorobenzamide N-(3-(6-amino-5-(2-(N-methylacrylamide) with physicochemical properties )Ethoxy)pyrimidin-4-yl)-5-fluoro-2-methylphenyl)-4-cyclohexyl There is a need to provide a solid form of propyl-2-fluorobenzamide.
[0007] N-(3-(6-amino-5-(2-(N-methylacrylamide)ethoxy)pyrimidinyl) 4-cyclopropyl-2-phenyl-5-fluoro-2-methylphenyl The compound is disclosed in International Publication No. 2015 / 07, filed on November 28, 2014. It was first disclosed in Example 6 of US Pat. No. 9417, which is incorporated herein by reference. The entirety of which is incorporated by reference. arylamide)ethoxy)pyrimidin-4-yl)-5-fluoro-2-methylphenyl) 4-Cyclopropyl-2-fluorobenzamide is represented by the formula (I): [ka] It is a Bruton's tyrosine kinase (BTK) inhibitor having the following structure:
[0008] However, WO 2015 / 079417 brochure states that N-(3-(6 -Amino-5-(2-(N-methylacrylamide)ethoxy)pyrimidin-4-yl -5-fluoro-2-methylphenyl)-4-cyclopropyl-2-fluorobenzamide The authors did not provide any information on the crystalline form of the drug. N-(3-(6-amino-5-(2-(N-methylacrylamide)) useful in the treatment of diseases Ethoxy)pyrimidin-4-yl)-5-fluoro-2-methylphenyl)-4-cyclo Crystalline forms of propyl-2-fluorobenzamide have been discovered. Conditions may include inflammatory and autoimmune disorders, as well as inflammation of the lungs and airways.
[0009] overview In one aspect, the present invention provides N-(3-(6-amino-5- (2-(N-methylacrylamide)ethoxy)pyrimidin-4-yl)-5-fluoro Three crystals of (2-methylphenyl)-4-cyclopropyl-2-fluorobenzamide In certain embodiments, the free form is an anhydrous form of the compound of formula (I). be.
[0010] These crystalline form embodiments are designated herein as Form A, Form B, and Form C. The names used herein to identify particular forms (e.g. , "Form A", "Form B", or "Form C") have similar or identical physical properties. should be considered definitive with respect to any other substance that has the characteristics and chemical properties Rather, these nomenclature is based on the characterization presented herein. It should be understood that they are merely identifiers to be interpreted according to the information.
[0011] In one aspect, the present invention also provides a method for producing a compound comprising the steps of: (a) N-(3-(6-amino-5-(2-(N-methyl Acrylamide)ethoxy)pyrimidin-4-yl)-5-fluoro-2-methylphenyl a therapeutically effective amount of crystalline form A of 4-cyclopropyl-2-fluorobenzamide; and (b) at least one pharma- ceutically acceptable carrier. Alternatively, crystalline form A is substantially pure. More preferably, form A is substantially phase pure. That's cool.
[0012] In one aspect, the present invention also provides a method for producing a compound comprising the steps of: (a) N-(3-(6-amino-5-(2-(N-methyl Acrylamide)ethoxy)pyrimidin-4-yl)-5-fluoro-2-methylphenyl a therapeutically effective amount of crystalline form B of 4-cyclopropyl-2-fluorobenzamide; and (b) at least one pharma- ceutically acceptable carrier. Alternatively, crystalline form B is substantially pure. More preferably, form B is substantially phase pure. That's cool.
[0013] In one aspect, the present invention also provides a method for the preparation of a compound comprising the steps of: ethoxy)pyrimidin-4-yl)-5-fluoro-2-methylphenyl)- A process for preparing crystalline form A of 4-cyclopropyl-2-fluorobenzamide, comprising the steps of: a) optionally in the presence of an inorganic base, in a non-chlorinated solvent; N-(3-(6-amino-5-(2-methylamino) Ethoxy)pyrimidin-4-yl)-5-fluoro-2-methylphenyl)-4-cyclo reacting propyl-2-fluorobenzamide with acrylic anhydride; and b) converting the product into a solid (e.g., by antisolvent crystallization, cooling crystallization, distillation procedures, or evaporation of the solvent) and isolating crystalline form A. Also provided is a method comprising:
[0014] In one aspect, the present invention also provides a method for treating cancers mediated by or ameliorated by inhibition of BTK. A method for treating a disorder characterized by the initiation of treatment of a patient in need of such treatment, comprising administering to said patient an N-(3-(6-amino) No-5-(2-(N-methylacrylamide)ethoxy)pyrimidin-4-yl)-5- Fluoro-2-methylphenyl)-4-cyclopropyl-2-fluorobenzamide Also provided are methods comprising administering a therapeutically effective amount of crystalline form A. Preferably, the crystalline form A is substantially phase pure.
[0015] In one aspect, the present invention also provides a method for treating cancers mediated by or ameliorated by inhibition of BTK. A method for treating a disorder characterized by the initiation of treatment of a patient in need of such treatment, comprising administering to said patient an N-(3-(6-amino) No-5-(2-(N-methylacrylamide)ethoxy)pyrimidin-4-yl)-5- Fluoro-2-methylphenyl)-4-cyclopropyl-2-fluorobenzamide Also provided is a method comprising administering an effective amount of qualitatively phase pure crystalline Form B. Preferably , crystalline form B is substantially phase pure.
[0016] In one aspect, the present invention also provides a method for treating cancers mediated by or ameliorated by inhibition of BTK. N-(3-(6-amino-5-(2-(N-methyl)) for the preparation of a medicament for the treatment of disorders (Ethoxy)pyrimidin-4-yl)-5-fluoro-2-methylphenyl The present invention also provides the use of crystalline form A of (4-cyclopropyl-2-fluorobenzamide)- Preferably, crystalline form A is substantially phase pure.
[0017] In one aspect, the present invention also provides a method for treating cancers mediated by or ameliorated by inhibition of BTK. N-(3-(6-amino-5-(2-(N-methyl)) for the preparation of a medicament for the treatment of disorders (Ethoxy)pyrimidin-4-yl)-5-fluoro-2-methylphenyl Substantially phase-pure crystalline form B of (4-cyclopropyl-2-fluorobenzamide Preferably, crystalline form B is substantially phase pure.
[0018] In one aspect, the present invention also provides a method for treating cancers mediated by or ameliorated by inhibition of BTK. N-(3-(6-amino-5-(2-(N-methylacrylamide) for use in the treatment of disorders arylamide)ethoxy)pyrimidin-4-yl)-5-fluoro-2-methylphenyl) Also provided is crystalline form A of -4-cyclopropyl-2-fluorobenzamide. , crystalline form A is substantially phase pure.
[0019] In one aspect, the present invention also provides a method for treating cancers mediated by or ameliorated by inhibition of BTK. N-(3-(6-amino-5-(2-(N-methylacrylamide) for use in the treatment of disorders arylamide)ethoxy)pyrimidin-4-yl)-5-fluoro-2-methylphenyl) Also provided is a substantially phase-pure crystalline form B of 4-cyclopropyl-2-fluorobenzamide. Preferably, crystalline form B is substantially phase pure.
[0020] Thus, the crystalline forms of the compounds of formula (I) described herein are mediated by BTK. The present invention is useful in the treatment of the following diseases or disorders that are prevented or ameliorated by inhibition of BTK: Autoimmune disorders, inflammatory diseases, allergic diseases, airway diseases such as asthma and chronic obstructive pulmonary disease disease (COPD), transplant rejection; antibody production, antigen presentation, cytokine production, or lymphoma Diseases in which tissue formation is abnormal or undesirable; e.g., rheumatoid arthritis, systemic juvenile idiopathic arthritis Somatic arthritis of the aged (SOJIA), gout, pemphigus vulgaris, idiopathic thrombocytopenic purpura, systemic erythematosus Lymetomatosus, multiple sclerosis, myasthenia gravis, Sjögren's syndrome, autoimmune hemolytic Anemia, antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis, cryoglobulinemia, thrombotic microenvironment Thrombocytopenic purpura, chronic urticaria (chronic idiopathic urticaria, induced urticaria), chronic allergy (A atopic dermatitis, contact dermatitis, allergic rhinitis), atherosclerosis, type 1 diabetes Diabetes mellitus, type 2 diabetes, inflammatory bowel disease, ulcerative colitis, Crohn's disease n), pancreatitis, glomerulonephritis, Goodpasture's syndrome, Hashimoto's thyroiditis, Graves' disease, antibodies AMR, graft-versus-host disease, B cell-mediated hyperacute, acute, and Diffuse transplant rejection; thromboembolic disorders, myocardial infarction, angina, stroke, ischemic disorders, pulmonary Embolism; cancer of the hematopoietic organs, including, but not limited to, multiple myeloma; leukemia; acute myeloid leukemia Hematologic malignancies; chronic myeloid leukemia; lymphocytic leukemia; myeloid leukemia; non-Hodgkin's lymphoma; lymphoma polycythemia vera; essential thrombocythemia; myelofibrosis with myeloid metaplasia; and Waldenstrom disease. Ström's disease.
[0021] The crystalline forms of the compound of formula (I) are useful in the treatment of rheumatoid arthritis; chronic urticaria, preferably chronic idiopathic urticaria; Particularly useful in the treatment of measles; Sjogren's syndrome, multiple sclerosis, atopic dermatitis, or asthma. It is useful. [Brief description of the drawings]
[0022] [Figure 1] 1 shows an illustrative XRPD spectrum of the anhydrous crystalline form of compound of formula (I), designated herein as Form A, showing the angle 2θ (2 theta) on the X-axis and the relative intensity on the Y-axis. [Diagram 2] 1 shows an exemplary DSC of the anhydrous crystalline form of the compound of formula (I), designated herein as Form A. [Diagram 3] 1 shows an exemplary TGA of the anhydrous crystalline form of the compound of formula (I), designated herein as Form A. [Figure 4]1 shows an illustrative XRPD spectrum of the anhydrous crystalline form of compound of formula (I), designated herein as Form B, showing the angle 2θ (2 theta) on the X-axis and the relative intensity on the Y-axis. [Diagram 5] 1 shows an exemplary DSC of the anhydrous crystalline form of the compound of formula (I), designated herein as Form B. [Figure 6] 1 shows an exemplary TGA of the anhydrous crystalline form of the compound of formula (I), designated herein as Form B. [Figure 7] 1 shows an illustrative XRPD spectrum of the anhydrous crystalline form of compound of formula (I), designated herein as Form C, showing the angle 2θ (2 theta) on the X-axis and the relative intensity on the Y-axis. [Figure 8] 1 shows an exemplary DSC of the anhydrous crystalline form of the compound of formula (I), designated herein as Form C. [Figure 9] 1 shows an exemplary TGA of the anhydrous crystalline form of the compound of formula (I), designated herein as Form C.
[0023] A more detailed list of the XRPD peaks for each of Forms A, B, and C are set forth in the tables below, respectively. 1 and 2, in which the % relative intensity (I / I 0 × 100) is also listed. X-ray powder diffraction spectra or patterns are subject to instrumental variability (e.g., As a result of the differences in the angle 2θ (including the difference in It should be understood that XRPD peak measurements are therefore limited to a maximum variation of ±0.2° 2θ. Although fluctuations exist, even such peak values are within the range of the crystalline materials described herein. It should be understood that the XRPD data may be considered representative of a particular solid form of the compound. Other measurements from the experiments and DSC / TGA experiments (e.g., relative intensity and water content) were For example, variations may occur as a result of sample preparation and / or storage and / or environmental conditions. However, even this measurement may vary depending on the particular solid state form of the crystalline material described herein. It should be understood that the above is considered representative of the
[0024] Detailed Description of the Disclosure definition As used herein, the terms "about" and "substantially" refer to characteristics (e.g., endothermic These values may vary with respect to the amount of heat absorbed, endothermic peaks, exothermic values, baseline shifts, etc. With respect to X-ray diffraction peak positions, "about" or "substantially" indicates a typical This means that variations in peak position and intensity are taken into account. For example, one skilled in the art would It will be appreciated that the measurement (2θ) will exhibit some inter-instrument variation (typically on the order of 0.2°). In some cases, this variation can be higher than 0.2° depending on the calibration difference of the device. Additionally, those skilled in the art will appreciate that the relative peak intensities may vary depending on instrumental variation, as well as crystallinity, preferred orientation, and preparation. The variation due to the prepared sample surface and other factors known to those skilled in the art is shown and used as a qualitative measure. In the case of DSC, the observed temperature changes should be interpreted only as a function of the The behavior depends on the rate of temperature change as well as the sample preparation technique and the particular instrument used. Therefore, the endothermic / thermal events reported herein for the DSC / TGA thermograms are The melting point values may vary by ±5°C (but still fall within the range of the specific melting points described herein). Other characteristics (e.g., weight percent (wt%), When used in the context of reaction temperatures, the term "about" indicates a variance of ±5%.
[0025] The term "crystalline form", or "crystalline modification", or "polymorphic form", or "polymorph" means a compound of the formula The terms are used interchangeably herein. As used herein, "polymorphs" refers to compounds having the same chemical composition. Crystal forms that are the same but differ in the spatial arrangement of the molecules, atoms, and / or ions that form the crystals Each polymorph differs in thermodynamic stability, physical parameters, X-ray structure, and preparation method. become.
[0026] As used herein, "amorphous" refers to a material that is in a crystalline form, such as a molecule, atom, and / or ion. Amorphous solids do not show distinct X-ray diffraction patterns.
[0027] As used herein, "substantially pure" when used in reference to a form Based on the weight of the compound of formula (I), more than 90% by weight of this compound (e.g., 90, 91 , 92, 93, 94, 95, 96, 97, 98, and greater than 99% by weight, and about 100% by weight %) purity. The remaining material may be other forms of this compound and / or includes reaction impurities and / or process impurities arising from its preparation. For example, The crystalline forms are those currently known and generally accepted in the art. Substantially pure in that it has a purity of greater than 90% by weight as measured by any suitable means. and the remaining less than 10% by weight of the material may be considered to be other forms of the compound of formula (I) and / or includes reaction impurities and / or processing impurities.
[0028] As used herein, "substantially phase pure" refers to any crystalline form of the compound of formula (I). When used in relation to the form, this is based on the weight of the compound of formula (I) on an anhydrous basis. More than about 90% by weight of the compound (e.g., about 90, 91, 92, 93, 94, 95, 96, 97 %, 98, and greater than about 99% by weight, and about 100% by weight. The term "phase pure" or "phase purity" is used herein to refer to a particular phase of a compound of formula (I). Refers to phase homogeneity with respect to solid form, not necessarily a high degree of homogeneity, unless expressly stated to that effect. No particular chemical purity is implied by the use of any of the compounds known in the art. Using this approach (e.g., identifying lines (peaks) due to different phases in a particular spectrum) (c) direct comparison of characteristics by external standard method, or (d) quantitative phase separation by internal standard method. Phase purity was determined according to methods known in the art using XRPD to perform the analysis. However, XRPD quantification of phase purity is complicated by the presence of non-crystalline material. Therefore, other methods that may be useful for determining phase purity include, for example, solid N MR spectroscopy, Raman spectroscopy, and / or infrared spectroscopy. and how these additional (or alternative) methods are used to determine phase purity. You will easily understand.
[0029] As used herein, "substantially chemically pure" refers to any of the compounds of formula (I) When used in reference to a crystalline form, it is based on the weight of the compound of formula (I) on an anhydrous basis. , more than about 90% by weight of this compound (e.g., about 90, 91, 92, 93, 94, 95, 96 , 97, 98, and greater than about 99% by weight, and about 100% by weight. The remaining material may be other compounds (e.g., other stereoisomers of the compound of formula (I)). ), reaction impurities, starting materials, reagents, by-products, and / or the preparation and / or synthesis of particular crystalline forms. or other processing impurities resulting from isolation and / or purification. For example, The crystalline forms of compound (I) are standard and generally accepted forms known in the art. It has been determined to have a chemical purity of greater than about 90% by weight, as measured by methods known in the art. can be considered substantially chemically pure, with the remaining less than about 10% by weight being free of other substances. (e.g., other stereoisomers of the compound of formula (I), reaction impurities, starting materials, reagents, by-products, Chemical purity is determined according to methods known in the art. For example, high performance liquid chromatography (HPLC), LC-MS (liquid crystallography), The chromatographic and mass spectrometry, nuclear magnetic resonance (NMR) spectroscopy, or infrared spectroscopy are used to determine the Those skilled in the art will be familiar with these methods and these additional ( It will be readily apparent to those skilled in the art how to use the method (or alternative) to
[0030] As used herein, the term "seed" refers to one or more crystalline compounds of formula (I). The term "seed" may also be used as a noun to describe multiple crystals. The one or more crystals of the crystalline compound of and introducing the compound of formula (I) into the mixture, suspension, or dispersion, thereby resulting in the formation of more crystals or As a verb to describe the action of causing the growth of introduced crystals of a crystalline compound It can also be used.
[0031] The term "therapeutically effective amount" of a compound of the invention refers to a therapeutically effective amount that is effective to induce a biological or medical response in a subject. Answer (e.g., reduction or inhibition of enzyme or protein activity, or amelioration of symptoms, condition The compounds of the present invention induce a therapeutic effect, such as alleviating the symptoms of a disease, slowing or delaying the progression of the disease, or preventing the disease. In one non-limiting embodiment, the term "therapeutically effective amount" refers to an amount of (1) (i) mediated by BTK, or (ii) inhibiting BTK activity when administered or (iii) a condition characterized by activity (normal or abnormal) of BTK. or at least partially ameliorate, inhibit, or prevent a disorder or disease. (2) reduce or inhibit the activity of BTK. or (3) a method of the invention that is effective to reduce or inhibit the expression of BTK. In another non-limiting embodiment, the term "therapeutically effective amount" refers to an amount of a compound. The activity of BTK when administered to cells, tissues, non-cellular biological material, or culture medium. or at least partially reduce or inhibit the expression of BTK. "Amount of compound of the present invention effective to completely reduce or inhibit the progression of the disease" refers to an amount of a compound of the present invention effective to completely reduce or inhibit the progression of the disease.
[0032] As used herein, the term "subject" refers to an animal. The subject is a mammal. The subject may be, for example, a primate (e.g., a human), a cow, a sheep, a goat, Horses, dogs, cats, rabbits, rats, mice, fish, birds, and the like. In an embodiment, the subject is a human.
[0033] As used herein, a subject is a person who has undergone a treatment to treat a disease or condition that is caused by a biological or medical condition. If such a procedure would benefit the patient in terms of the quality of life or the ability to live with the disease, "in need of" or "in need thereof" )".
[0034] As used herein, the terms "a," "an," "the," and "the" refer to the Similar terms used in context (especially in the context of the claims) will be interpreted differently in this specification. Unless otherwise specified or clearly contradicted by the context, both the singular and the plural are intended to be encompassed. It should be.
[0035] Unless otherwise indicated herein or clearly contradicted by context, All disclosed methods may be performed in any suitable order. The use of any examples or exemplary language (eg, "such as") merely illustrates the invention. and, unless otherwise stated, is intended to provide a more complete understanding of the present invention. This does not limit the following.
[0036] As used herein, "inhibit" and "inhibit The terms "inhibition" and "inhibiting" refer to a given Alleviation or suppression of a condition, symptom, or disorder, or disease, or biological activity or indicates a significant decrease in the baseline activity of a process.
[0037] As used herein, the term "treat" or "treatment" refers to any disease or disorder. The terms "treating" or "treatment" are used interchangeably. In one embodiment, the method comprises ameliorating the disease or disorder (i.e., alleviating the disease or clinical symptoms thereof). (Delaying, stopping, or reducing the development of at least one of the following: In another embodiment, "treat" or "treating" is used. ""or"treatment"" may not be recognized by the patient. It refers to reducing or ameliorating at least one physical parameter, including In yet another embodiment, the term "treat" or "treat g) or "treatment" means the physical (e.g., relief of discernible symptoms) The disease or disorder may be prevented or prevented in a variety of ways, including physiological (e.g., stabilization of a physical parameter), or both. In one embodiment, "treat" or "treating" refers to modulating the harm. "Treating" refers to slowing the progression of a disease or disorder.
[0038] As used herein, "prevent" any disease or disorder, "Preventing" or "prevention" The term "prophylactic treatment of the disease or disorder" refers to the prevention of the disease or disorder; or the delay of the onset of the disease or disorder. It means to extend.
[0039] The term "comprising" includes "including" and and "consisting of", e.g., a composition containing X means that it contains only X. or may include further ones (e.g. X and Y).
[0040] As used herein, the term "combination" refers to a fixed combination in one unit dosage form. It refers to a combination or a crystalline form of a compound of formula (I) and a combination partner (i.e. , immunotherapeutic agent) can be administered simultaneously or separately within a time interval. In particular, this time interval may be set so that the combination partners have a synergistic effect (e.g., a synergistic effect). The single components are packaged in a kit. One or both of the components (e.g., powder or liquid) may be It may be reconstituted or diluted to the desired dose prior to administration.
[0041] The terms "co-administration" or "administration in combination" or the like are used herein. When utilized, the administration of a selected combination partner to a single subject (e.g., a patient) in need thereof administration, and does not necessarily mean that the drugs are administered by the same route or at the same time. The present invention is intended to include treatment regimens in which no
[0042] The terms "pharmaceutical combination" and "combination product" are used interchangeably and are intended to mean any combination of refers to a fixed combination in one unit dosage form, or two or more therapeutic agents are administered simultaneously and independently The combination may be administered or may be administered separately within a time interval, particularly if the time interval is longer than the time interval. A combination that allows the combination partners to exhibit a synergistic effect (e.g., synergy). "Fixed combination" refers to a non-fixed combination or kit of elements for administration. The term refers to a crystalline form of a compound of formula (I) and a combination partner (i.e., an immunotherapeutic agent). is meant to be administered to a patient simultaneously in the form of a single entity or dosage. The term "non-fixed combination" refers to the crystalline forms and combination parts of the compound of formula (I). The agents (i.e., immunotherapeutic agents) are administered simultaneously. both as separate entities, either continuously without any specific time limit, or is also meant to be administered to a patient, such administration resulting in the synthesis of two compounds in the patient's body. The latter also provides therapeutically effective levels of the agent. In a preferred embodiment, the pharmaceutical combination is a non-fixed combination. It is a combination.
[0043] The term "combination therapy" refers to a combination therapy for treating a BTK-related disease as described in this disclosure. Such administration refers to the administration of two or more therapeutic agents for the treatment of a disease with a fixed ratio of active ingredients. or the co-administration of these therapeutic agents in a substantially simultaneous manner, such as in one capsule; or Such administration may be accomplished by administering multiple or separate containers (e.g., tablets, capsules, etc.) for each active ingredient. The powder and / or liquid may be mixed with the desired amount prior to administration. In addition, such administration may also be approximately simultaneous or This also includes the use of each type of therapeutic agent in a sequential manner, either at different times. In any case, the treatment regimen includes treatment of a condition or disorder described herein. This will provide a beneficial effect of the drug combination in this setting.
[0044] Crystalline form: The present disclosure relates to the N-(3-(6 -Amino-5-(2-(N-methylacrylamide)ethoxy)pyrimidin-4-yl -5-fluoro-2-methylphenyl)-4-cyclopropyl-2-fluorobenzamide The present invention relates to an anhydrous crystalline form of compound of formula (I).
[0045] In one embodiment, the present disclosure provides a method for the preparation of a soluble ... N with an X-ray powder diffraction (XRPD) pattern containing representative peaks (in terms of °2θ) -(3-(6-amino-5-(2-(N-methylacrylamide)ethoxy)pyrimidine -4-yl)-5-fluoro-2-methylphenyl)-4-cyclopropyl-2-fluoro In another embodiment, the XRPD pattern is The angles were 15.6±0.2°2θ, 18.3±0.2°2θ, and 23.4±0.2°2θ. The present invention further includes one or more additional representative peaks selected from θ. In one embodiment, the XRPD pattern has a molecular weight of 7.8±0.2° C., measured at a temperature of about 25° C. 2θ, 13.6±0.2°2θ, 19.2±0.2°2θ, 19.9±0.2°2θ, and and 29.6±0.2° 2θ. In one aspect of the above embodiment, the XRPD pattern of crystalline form A of compound of formula (I) is are measured at a temperature of about 25°C, 9.2±0.2°2θ, 12.0±0.2°2θ, 1 7.8±0.2°2θ, 18.7±0.2°2θ, 19.2±0.2°2θ, 19.9± 0.2° 2θ, 25.2±0.2° 2θ, and 29.6±0.2° 2θ The compound of formula (I) may further include one, two, three, or four representative peaks. The XRPD pattern of crystalline form A of the compound was 7.8±0.05 μm when measured at a temperature of about 25° C. .2°2θ, 9.2±0.2°2θ, 12.0±0.2°2θ, 13.6±0.2°2θ , 15.6±0.2°2θ, 16.0±0.2°2θ, 17.8±0.2°2θ, 18. 3±0.2°2θ, 18.7±0.2°2θ, 19.2±0.2°2θ, 19.9±0. 2°2θ, 22.1±0.2°2θ, 23.4±0.2°2θ, 23.9±0.2°2θ , 24.8±0.2°2θ, 25.2±0.2°2θ, 25.5±0.2°2θ, 27. 2±0.2°2θ, and 29.6±0.2°2θ The XRPD pattern of crystalline form A is disclosed in Table 1 and may include peaks of about 2 One or more peaks (e.g., 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, The representative peaks may include one, five, or six.
[0046] In another aspect of the above embodiment, crystalline form A of the compound of formula (I) is obtained when measured at a temperature of about 25° C. When the angle is set to 7.8±0.2°2θ, 9.2±0.2°2θ, and 12.0±0.2°2θ, , 13.6±0.2°2θ, 15.6±0.2°2θ, 16.0±0.2°2θ, 17. 8±0.2°2θ, 18.3±0.2°2θ, 18.7±0.2°2θ, 19.2±0. 2°2θ, 19.9±0.2°2θ, 22.1±0.2°2θ, 23.4±0.2°2θ , 23.9±0.2°2θ, 24.8±0.2°2θ, 25.2±0.2°2θ, 25. From the group consisting of 5±0.2°2θ, 27.2±0.2°2θ, and 29.6±0.2°2θ X-ray powder diffraction patterns containing four or more 2θ values (CuKαλ=1.54184Å) selected from In another aspect of the above embodiment, crystalline form A of the compound of formula (I) is characterized by: 7.8±0.2°2θ, 9.2±0.2°2θ, 12.0 ±0.2°2θ, 13.6±0.2°2θ, 15.6±0.2°2θ, 16.0±0.2 °2θ, 17.8±0.2°2θ, 18.3±0.2°2θ, 18.7±0.2°2θ, 19.2±0.2°2θ, 19.9±0.2°2θ, 22.1±0.2°2θ, 23.4 ±0.2°2θ, 23.9±0.2°2θ, 24.8±0.2°2θ, 25.2±0.2 °2θ, 25.5±0.2°2θ, 27.2±0.2°2θ, and 29.6±0.2°2θ θ includes 5 or more 2θ values (CuKαλ=1.54184Å) selected from the group consisting of Characterized by X-ray powder diffraction pattern.
[0047] In yet another aspect of the above embodiment, the crystalline form A of the compound of formula (I) is substantially similar to that shown in FIG. It has the XRPD pattern shown in.
[0048] N-(3-(6-amino-5-(2-(N-methylacrylamide)ethoxy)pyrimidinyl) 4-cyclopropyl-2-phenyl-5-fluoro-2-methylphenyl Crystalline Form A of fluorobenzamide may be thermally characterized. In one embodiment, Crystalline form A of the compound of formula (I) exhibits a single endothermic peak with an onset of about 194° C. (corresponding to melting). The thermal conductivity was measured by differential scanning calorimetry (DSC) with a heating rate of 10°C / min. Has a thermal profile.
[0049] In another embodiment, the crystalline form A of the compound of formula (I) is substantially as shown in FIG. The hydrated form varies depending on the instrument parameters (peak shape and peak This may result in different thermograms (with respect to the profile) and therefore the data may be The same substances may appear substantially different from each other if they are produced in different equipment. It should be understood that the thermogram may vary.
[0050] In another embodiment, the crystalline form A of the compound of formula (I) is substantially similar to that shown in FIG. The thermogravimetric analysis (TGA) diagrams are essentially identical. The weight loss by TGA is 40 About 0.3% in the range of ~200°C. Thermal decomposition occurred at 240°C.
[0051] In yet another embodiment, crystalline form A is substantially pure.
[0052] In yet another embodiment, crystalline form A is substantially chemically pure.
[0053] In yet another embodiment, crystalline form A is substantially phase pure.
[0054] In one embodiment, the present invention provides the compound N-(3-(6-amino-5-(2-(N-methyl Acrylamide)ethoxy)pyrimidin-4-yl)-5-fluoro-2-methylphenyl A method for producing crystalline form A of 4-cyclopropyl-2-fluorobenzamide. So, a) by reacting N-(3-(6-aminophenyl)phenyl)-2-(2-phenylpropanediol in a non-chlorinated solvent, optionally in the presence of an inorganic base; No-5-(2-(methylamino)ethoxy)pyrimidin-4-yl)-5-fluoro-2 (Methylphenyl)-4-cyclopropyl-2-fluorobenzamide and acrylic anhydride A process of reacting with something; and b) converting the product into a solid (e.g., by antisolvent crystallization, cooling crystallization, distillation procedures, or evaporation of the solvent) and isolating crystalline form A. The present invention relates to a method comprising the steps of:
[0055] In another embodiment, the present invention relates to the compound N-(3-(6-amino-5-(2-(N-methyl (Ethoxy)pyrimidin-4-yl)-5-fluoro-2-methylphenyl A method for preparing crystalline form A of (4-cyclopropyl-2-fluorobenzamide) There was, (a) reacting N-(3-(6-aminophenyl)phenyl)-2-(2-phenylpropanediol with N-(3-(6-aminophenyl)-2-(2-phenylpropanediol) in a non-chlorinated solvent, optionally in the presence of a base; -5-(2-(methylamino)ethoxy)pyrimidin-4-yl)-5-fluoro-2- Methylphenyl)-4-cyclopropyl-2-fluorobenzamide and acrylic anhydride reacting with; (b) adding water to quench the reaction forming an aqueous phase and an organic phase; (c) separating the organic phase; (d) washing the organic phase with an acidic solution; and (e) a solid (e.g., by anti-solvent crystallization, cooling crystallization, distillation procedures, or evaporation of the solvent) isolating crystalline form A as The present invention relates to a method comprising the steps of:
[0056] In one aspect of the previous two embodiments, step (a) of the method is carried out at a temperature of about 20° C. to about 65° C. Preferably, step (a) is carried out at a temperature of about 40° C. to about 65° C., most preferably The reaction is carried out at a temperature of about 50°C.
[0057] In yet another aspect of the previous three embodiments, step (a) of the process is performed with ethyl acetate and isopropyl acetate, and preferably ethyl acetate. To carry out.
[0058] In yet another aspect of the previous four embodiments, step (a) is carried out in the presence of an inorganic base. Preferably, the reaction is carried out in the presence of a carbonate base, more preferably in the presence of sodium carbonate. To carry out.
[0059] In another aspect of the above five embodiments, the method further comprises the step of: and heating the reaction mixture to a temperature of about 50° C. to about 65° C. before the step (c). ) cooling to room temperature prior to the addition of the acrylic acid. This may be useful to remove the acid by-products more efficiently.
[0060] In another aspect of the previous six embodiments, the acidic solution used in step (d) has a pH of about 1. For example, the acid solution is a sulfuric acid solution (e.g., 0.05M). The reaction mixture was washed with the solution to remove the following by-products: [ka] Remove.
[0061] In yet another aspect of the above seven embodiments, Form A is obtained by anti-solvent crystallization as a solid. An anti-solvent is a solvent in which the compound of formula (I) has low solubility (e.g., less than 0.5 mg / mL). In this method, the solubility of the solvent is less than 0.25 mg / mL. Non-limiting examples of anti-solvents for use include heptane, hexane, t-butyl methyl ether, The solvent is toluene, or acetonitrile.
[0062] In a further preferred aspect of the above seven embodiments, Form A is obtained as a solid by a distillation procedure. Isolate.
[0063] The present invention also relates to a method for producing N-(3-(6-amino-5-(2-(N-methylacrylamide) ester) (5-fluoro-2-methylphenyl)-4-cyclopropoxy A process for preparing Form A of propyl-2-fluorobenzamide comprising the steps of: (a) N-(3-(6-amino-5-(2-(N-methylacrylamide)ethoxy) pyrimidin-4-yl)-5-fluoro-2-methylphenyl)-4-cyclopropyl- Crystalline form B of 2-fluorobenzamide; or N-(3-(6-amino-5-(2-(N -Methylacrylamide)ethoxy)pyrimidin-4-yl)-5-fluoro-2-methyl 4-cyclopropyl-2-fluorobenzamide; or suspending the mixture of B and Form C in a non-chlorinated solvent; and (b) a solid (e.g., by anti-solvent crystallization, cooling crystallization, distillation procedures, or evaporation of the solvent) isolating Form A as Also provided is a method comprising:
[0064] The present invention also relates to a method for producing N-(3-(6-amino-5-(2-(N-methylacrylamide) ester) (5-fluoro-2-methylphenyl)-4-cyclopropoxy A process for preparing Form A of propyl-2-fluorobenzamide comprising the steps of: (a) N-(3-(6-amino-5-(2-(N-methylacrylamide)ethoxy) pyrimidin-4-yl)-5-fluoro-2-methylphenyl)-4-cyclopropyl- Crystalline form B of 2-fluorobenzamide; or N-(3-(6-amino-5-(2-(N -Methylacrylamide)ethoxy)pyrimidin-4-yl)-5-fluoro-2-methyl 4-cyclopropyl-2-fluorobenzamide; or suspending the mixture of B and Form C in a non-chlorinated solvent; and (b) Allow the suspension to equilibrate at room temperature for at least two weeks or Equilibrating the solution at 50° C. for at least one week; and (c) a solid (e.g., by anti-solvent crystallization, cooling crystallization, distillation procedures, or evaporation of the solvent) isolating Form A as Also provided is a method comprising:
[0065] In one aspect of the previous two embodiments, the non-chlorinated solvent is 1,4-dioxane, alcohol , acetone, acetonitrile, tetrahydrofuran, water, pyridine, nitromethane, aniline and alkyl acetate.
[0066] In yet another aspect of the previous three embodiments, crystalline form B, or crystalline form C, or a mixture thereof, The mixture may be dissolved in a non-chlorinated solvent. In such a case, it may be in the form of a solid. If isolating A involves anti-solvent crystallization, cooling crystallization, a distillation procedure, or evaporation of the solvent In other embodiments, Form B, Form C, or a mixture thereof may remain in suspension. In this case, Form A is isolated by filtration.
[0067] The present invention has a refractive index of 20.9±0.2 degrees 2θ (relative to degrees 2θ) when measured at a temperature of about 25° C. The X-ray powder diffraction (XRPD) pattern contains typical peaks for N-(3-(6 -Amino-5-(2-(N-methylacrylamide)ethoxy)pyrimidin-4-yl -5-fluoro-2-methylphenyl)-4-cyclopropyl-2-fluorobenzamide In another embodiment, the XRPD pattern is , 6.7±0.2°2θ, 11.1±0.2°2θ, when measured at a temperature of about 25°C, 17.9±0.2°2θ, 20.2±0.2°2θ, 20.9±0.2°2θ, and 24 0.0±0.2°2θ In one aspect of the above embodiment, the XRPD pattern of crystalline form B is measured at a temperature of about 25° C. When the angle is 5.9±0.2°2θ, 13.0±0.2°2θ, and 14.8±0.2°2θ, , 19.0±0.2°2θ, and 22.6±0.2°2θ The representative peaks may further include one or four representative peaks.
[0068] Therefore, the XRPD pattern of crystalline form B is 5.9±0.2°2θ, 6.7±0.2 °2θ, 7.8±0.2°2θ, 8.3±0.2°2θ, 11.1±0.2°2θ, 12 .1±0.2°2θ, 12.6±0.2°2θ, 13.0±0.2°2θ, 13.3±0 .2°2θ, 14.8±0.2°2θ, 15.8±0.2°2θ, 16.4±0.2°2 θ, 17.6±0.2°2θ, 19.5±0.2°2θ, 20.2±0.2°2θ, 20 .6±0.2°2θ, 20.9±0.2°2θ, 21.6±0.2°2θ, 22.3±0 .2°2θ, 23.3±0.2°2θ, 24.0±0.2°2θ, 24.9±0.2°2 θ, and 25.3±0.2°2θ (e.g., 2, 3, The XRPD pattern of crystalline form B may include typical peaks of 4, 5, or 6. The peaks are selected from the peaks disclosed in Table 2 and One or more (e.g., 2, 3, 4) , 5, or 6) representative peaks.
[0069] In another embodiment, the Form B has a viscosity of 5.9±0.2° C. measured at a temperature of about 25° C. θ, 6.7±0.2°2θ, 7.8±0.2°2θ, 8.3±0.2°2θ, 11.1± 0.2°2θ, 12.1±0.2°2θ, 12.6±0.2°2θ, 13.0±0.2° 2θ, 13.3±0.2°2θ, 14.8±0.2°2θ, 15.8±0.2°2θ, 1 6.4±0.2°2θ, 17.6±0.2°2θ, 19.5±0.2°2θ, 20.2± 0.2°2θ, 20.6±0.2°2θ, 20.9±0.2°2θ, 21.6±0.2° 2θ, 22.3±0.2°2θ, 23.3±0.2°2θ, 24.0±0.2°2θ, 2 4.9±0.2°2θ and 25.3±0.2°2θ It is characterized by an X-ray powder diffraction pattern with a 2θ value of (CuKαλ=1.54184 Å).
[0070] In another embodiment, the Form B has a viscosity of 5.9±0.2° C. measured at a temperature of about 25° C. θ, 6.7±0.2°2θ, 7.8±0.2°2θ, 8.3±0.2°2θ, 11.1± 0.2°2θ, 12.1±0.2°2θ, 12.6±0.2°2θ, 13.0±0.2° 2θ, 13.3±0.2°2θ, 14.8±0.2°2θ, 15.8±0.2°2θ, 1 6.4±0.2°2θ, 17.6±0.2°2θ, 19.5±0.2°2θ, 20.2± 0.2°2θ, 20.6±0.2°2θ, 20.9±0.2°2θ, 21.6±0.2° 2θ, 22.3±0.2°2θ, 23.3±0.2°2θ, 24.0±0.2°2θ, 2 Five or more selected from the group consisting of 4.9±0.2°2θ and 25.3±0.2°2θ It is characterized by an X-ray powder diffraction pattern with a 2θ value of (CuKαλ=1.54184 Å).
[0071] In yet another embodiment, the crystalline form B of the compound of formula (I) is substantially as shown in FIG. It has an XRPD pattern that is
[0072] N-(3-(6-amino-5-(2-(N-methylacrylamide)ethoxy)pyrimidinyl) 4-cyclopropyl-2-phenyl-5-fluoro-2-methylphenyl Crystalline form B of fluorobenzamide may be thermally characterized. In one embodiment, The crystalline form B of the compound of formula (I) exhibits an endothermic melting with an onset at about 170° C. (corresponding to the melting of modification B). peak, an exothermic peak beginning at about 175° C. (corresponding to recrystallization into modification A), and a The heating rate is 10 °C / min, including an exothermic peak beginning at 0 °C (corresponding to the melting of modification A). It has a differential thermogravimetric profile measured by DSC.
[0073] In another embodiment, the crystalline form B of the compound of formula (I) is substantially as shown in FIG. The hydrated form varies depending on the instrument parameters (peak shape and peak This may result in different thermograms (with respect to the profile) and therefore the data may be The same substances may appear substantially different from each other if they are produced in different equipment. It should be understood that the thermogram may vary.
[0074] In another embodiment, the crystalline form B of the compound of formula (I) is substantially the same as that shown in FIG. The thermogravimetric analysis (TGA) diagrams are essentially identical. The weight loss by TGA is 40 About 0.2% in the range of ~160°C. Thermal decomposition occurred above 240°C.
[0075] In yet another embodiment, crystalline form B is substantially pure.
[0076] In yet another embodiment, crystalline form B is substantially chemically pure.
[0077] In yet another embodiment, crystalline form B is substantially phase pure.
[0078] In one embodiment, the present invention provides the compound N-(3-(6-amino-5-(2-(N-methyl Acrylamide)ethoxy)pyrimidin-4-yl)-5-fluoro-2-methylphenyl A method for producing crystalline form B of 4-cyclopropyl-2-fluorobenzamide. So, (a) suspending Form A in dichloromethane at a temperature of about 40° C. for about 3 days; (b) allowing the suspension to equilibrate at room temperature for about 5 days; and (c) isolating Form B as a solid (e.g., by filtration). The present invention relates to a method comprising the steps of:
[0079] In yet another embodiment, the present invention relates to the compound N-(3-(6-amino-5-(2-(N -Methylacrylamide)ethoxy)pyrimidin-4-yl)-5-fluoro-2-methyl Preparation of Crystal Form B of (4-cyclopropyl-2-fluorobenzamide 1. A method comprising: a) suspending modification A in a solvent mixture containing at least 50% by volume of dichloromethane; Circumstances; b) allowing the suspension to equilibrate at a temperature of about 50° C. for about two weeks; c) cooling the suspension to room temperature; and d) isolating the solid from the suspension (e.g., by filtration). The present invention relates to a method comprising the steps of:
[0080] In one aspect of the above embodiment, the solvent mixture is MeOH / dichloromethane 50:50 (v / v).
[0081] The present invention has a refractive index of 5.9±0.2 degrees 2θ (in degrees 2θ) when measured at a temperature of about 25° C. The X-ray powder diffraction (XRPD) pattern contains typical peaks for N-(3-(6- Amino-5-(2-(N-methylacrylamide)ethoxy)pyrimidin-4-yl)- 5-Fluoro-2-methylphenyl)-4-cyclopropyl-2-fluorobenzamide In another embodiment, the XRPD pattern is When measured at a temperature of about 25°C, the values are 11.9±0.2°2θ, 17.0±0.2°2θ, and one or more additional representative peaks selected from 19.3±0.2° 2θ. In one aspect of the above embodiment, the XRPD pattern of crystalline form C is When measured in degrees, the angle is 12.5±0.2°2θ, 15.3±0.2°2θ, and 18.0±0 .2°2θ, 21.0±0.2°2θ, 21.2±0.2°2θ, 23.4±0.2°2 θ, and 23.7±0.2°2θ, It may further include peaks.
[0082] Therefore, the XRPD pattern of crystalline form C is 5.9±0.2°2θ, 11.9±0. 2°2θ, 12.0±0.2°2θ, 12.5±0.2°2θ, 12.9±0.2°2θ , 14.4±0.2°2θ, 14.6±0.2°2θ, 15.3±0.2°2θ, 17. 0±0.2°2θ, 18.0±0.2°2θ, 19.0±0.2°2θ, 19.2±0. 2°2θ, 19.9±0.2°2θ, 20.2±0.2°2θ, 20.8±0.2°2θ , 21.0±0.2°2θ, 21.2±0.2°2θ, 22.8±0.2°2θ, 23. 4±0.2°2θ, 23.7±0.2°2θ, 25.3±0.2°2θ, 26.1±0. 2° 2θ, and 26.9±0.2° 2θ (e.g., 2, The XRPD of crystalline form C may include representative peaks of at least one of the following: The patterns are selected from the peaks disclosed in Table 3 and are One or more (e.g., two, three) peaks measured at a temperature of about 25° C. , 4, 5, or 6) representative peaks.
[0083] In another embodiment, the Form C has a viscosity of 5.9±0.2° C. measured at a temperature of about 25° C. θ, 11.9±0.2°2θ, 12.0±0.2°2θ, 12.5±0.2°2θ, 12 .9±0.2°2θ, 14.4±0.2°2θ, 14.6±0.2°2θ, 15.3±0 .2°2θ, 17.0±0.2°2θ, 18.0±0.2°2θ, 19.0±0.2°2 θ, 19.2±0.2°2θ, 19.9±0.2°2θ, 20.2±0.2°2θ, 20 .8±0.2°2θ, 21.0±0.2°2θ, 21.2±0.2°2θ, 22.8±0 .2°2θ, 23.4±0.2°2θ, 23.7±0.2°2θ, 25.3±0.2°2 θ, 26.1±0.2°2θ, and 26.9±0.2°2θ The X-ray powder diffraction pattern is characterized by more than 2θ values (CuKαλ=1.54184Å). do.
[0084] In another embodiment, the Form C has a viscosity of 5.9±0.2° C. measured at a temperature of about 25° C. θ, 11.9±0.2°2θ, 12.0±0.2°2θ, 12.5±0.2°2θ, 12 .9±0.2°2θ, 14.4±0.2°2θ, 14.6±0.2°2θ, 15.3±0 .2°2θ, 17.0±0.2°2θ, 18.0±0.2°2θ, 19.0±0.2°2 θ, 19.2±0.2°2θ, 19.9±0.2°2θ, 20.2±0.2°2θ, 20 .8±0.2°2θ, 21.0±0.2°2θ, 21.2±0.2°2θ, 22.8±0 .2°2θ, 23.4±0.2°2θ, 23.7±0.2°2θ, 25.3±0.2°2 θ, 26.1±0.2°2θ, and 26.9±0.2°2θ The X-ray powder diffraction pattern is characterized by more than 2θ values (CuKαλ=1.54184Å). do.
[0085] In yet another embodiment, the crystalline form C of the compound of formula (I) is substantially as shown in FIG. It has an XRPD pattern that is
[0086] N-(3-(6-amino-5-(2-(N-methylacrylamide)ethoxy)pyrimidinyl) 4-cyclopropyl-2-phenyl-5-fluoro-2-methylphenyl Crystalline Form C of fluorobenzamide may be thermally characterized. In one embodiment, The crystalline form C of the compound of formula (I) can be obtained by the solid / solid transformation from modification C to modification B at 90-120°C. A small exothermic peak at 171 °C (corresponding to the melting of modification B) and an adsorption peak beginning at about 171 °C (corresponding to the melting of modification B). A thermal peak and an exothermic peak beginning at about 175° C. (corresponding to recrystallization into modification A) and a A heating rate of 10°C / min includes an endothermic peak beginning at 195°C (corresponding to the melting of modification A). The differential thermogravimetric profile measured by DSC is:
[0087] In another embodiment, the crystalline form C of the compound of formula (I) is substantially as shown in FIG. The hydrated form varies depending on the instrument parameters (peak shape and peak This may result in different thermograms (with respect to the profile) and therefore the data may be The same substances may appear substantially different from each other if they are produced in different equipment. It should be understood that the thermogram may vary.
[0088] In another embodiment, crystalline form C has a thermogravimetric analysis substantially identical to that shown in FIG. The weight loss by TGA is in the range of 40 to 150°C. Approximately 0.01%. Thermal decomposition occurred above 240°C.
[0089] In yet another embodiment, crystalline form C is substantially pure.
[0090] In yet another embodiment, crystalline form C is chemically phase pure.
[0091] In yet another embodiment, crystalline form C is substantially phase pure.
[0092] In one embodiment, the present invention provides the compound N-(3-(6-amino-5-(2-(N-methyl Acrylamide)ethoxy)pyrimidin-4-yl)-5-fluoro-2-methylphenyl A method for producing crystalline form C of 4-cyclopropyl-2-fluorobenzamide. So, a) suspending modification A in dichloromethane at a temperature of about 40° C. for about 3 days; b) cooling the suspension to room temperature; c) isolating Form C as a solid (e.g., by filtration). The present invention relates to a method comprising the steps of:
[0093] In another embodiment, the present invention relates to the compound N-(3-(6-amino-5-(2-(N-methyl (Ethoxy)pyrimidin-4-yl)-5-fluoro-2-methylphenyl A method for preparing crystalline form C of (4-cyclopropyl-2-fluorobenzamide) There was, a) suspending modification A in a solvent mixture comprising at least 50% dichloromethane; b) allowing the suspension to equilibrate at room temperature for approximately 4 weeks; c) isolating Form C as a solid (e.g., by filtration). The present invention relates to a method comprising the steps of:
[0094] In one aspect of the above embodiment, the solvent mixture is MeOH / dichloromethane 50:50 (v / v).
[0095] In another embodiment, the present invention relates to N-(3-(6-amino-5-(2-(N-methylacrylamide). arylamide)ethoxy)pyrimidin-4-yl)-5-fluoro-2-methylphenyl) Crystalline form of 4-cyclopropyl-2-fluorobenzamide (form A, form B, or A therapeutically effective amount of the combination of In certain embodiments, the present invention relates to a pharmaceutical composition comprising the crystalline form A pharmaceutical composition comprising Form A and one or more pharma- ceutically acceptable carriers, diluents, or excipients. In yet another aspect, the present invention relates to a composition comprising crystalline form A in a substantially phase pure form. In yet another aspect, the present invention relates to a pharmaceutical composition comprising a crystalline form of In yet another embodiment, the present invention relates to a pharmaceutical composition comprising crystalline form A. , and further N-(3-(6-amino-5-(2-(N-methylacrylamide)ethoxy )pyrimidin-4-yl)-5-fluoro-2-methylphenyl)-4-cyclopropyl The present invention relates to pharmaceutical formulations comprising at least one other solid form of 2-fluorobenzamide. In one aspect of this embodiment, the other solid form is crystalline form B. In this other solid form, N-(3-(6-amino-5-(2-(N-methylacrylamide) ethoxy)pyrimidin-4-yl)-5-fluoro-2-methylphenyl)- It is an amorphous form of 4-cyclopropyl-2-fluorobenzamide.
[0096] In another embodiment, the present invention provides a method for the preparation of a compound comprising administering to a subject a subject the steps of: arylamide)ethoxy)pyrimidin-4-yl)-5-fluoro-2-methylphenyl) Crystalline form of 4-cyclopropyl-2-fluorobenzamide (form A, form B, or A combination comprising a therapeutically effective amount of the combination of Specifically, it relates to pharmaceutical combinations.
[0097] In certain embodiments, the present invention provides a pharmaceutical composition comprising crystalline form A and one or more therapeutic agents. In yet another aspect, the present invention relates to a crystalline form in a substantially phase pure form. In yet another aspect, the present invention relates to a pharmaceutical combination comprising A and one or more therapeutic agents. The present invention relates to a pharmaceutical composition comprising crystalline form B in a substantially phase-pure form and one or more therapeutic agents. In yet another embodiment, the present invention relates to a combination comprising crystalline form A and N-(3-(6-amino-5-(2-(N-methylacrylamide)ethoxy)pyrimidinyl) (4-fluoro-2-methylphenyl)-5-fluoro-2-methylphenyl The present invention relates to a pharmaceutical combination comprising at least one other solid form of orobenzamide. In one aspect of the embodiment, the other solid form is crystalline form B. In yet another embodiment, Another solid form is N-(3-(6-amino-5-(2-(N-methylacrylamide). 5-fluoro-2-methylphenyl)-4-(2-methylphenyl)-5-fluoro-2-methylphenyl It is an amorphous form of cyclopropyl-2-fluorobenzamide.
[0098] In another embodiment, the present invention provides a pharmaceutical combination as described herein for the treatment of The therapeutic agent may be an immunosuppressant or immunomodulatory agent, or other anti-inflammatory agent (e.g., for allograft or acute or chronic rejection of xenografts, or inflammatory or autoimmune disorders from the group of anti-inflammatory agents for the treatment or prevention of inflammatory bowel disorders, or chemotherapeutic agents (e.g. malignant cell antiproliferative agents); The present invention provides pharmaceutical combinations, which are independently selected from the group consisting of crystalline forms of the compound of formula (I) and the compound of formula (I) may be used in combination with: calcineurin inhibitors, e.g., cyclosporine A or FK 506; mTOR inhibitors, such as rapamycin, 40-O-(2-hydroxybutyric acid (Droxyethyl)-rapamycin, CCI779, ABT578, AP23573, AP 23464, AP23675, AP23841, TAFA-93, Biolimus-7, or biolimus-9; ascomycins with immunosuppressive properties, e.g., ABT-28 1. ASM981, etc.; corticosteroids; cyclophosphamide; azathioprine (az athioprene); methotrexate; leflunomide; mizoribine; mycophenone mycophenolate mofetil; 15-deoxysperm Guarin, or an immunosuppressant homolog, analog, or derivative thereof; PKC Inhibitors, such as those described in WO 02 / 38561 or WO 03 / 828 PKC inhibitors disclosed in the pamphlet of No. 59, for example, those in Examples 56 or 70 Compounds; JAK3 kinase inhibitors, for example, N-benzyl-3,4-dihydroxy- Dylidene-cyanoacetamide α-cyano-(3,4-dihydroxy)-]N-benzyl Cinnamamide (Tyrphostin AG 490), Prodigiosin 25-C ( PNU156804), [4-(4'-hydroxyphenyl)-amino-6,7-dimeth quinazoline] (WHI-P131), [4-(3'-bromo-4'-hydroxyl (phenyl)-amino-6,7-dimethoxyquinazoline](WHI-P154), [4-(3 ',5'-Dibromo-4'-hydroxyphenyl)-amino-6,7-dimethoxyquinone Zolin] WHI-P97, KRX-211, in free form or in pharma- ceutically acceptable salt form (e.g., monocitrate) (also called CP-690,550) )-4-Methyl-3-[methyl-(7H-pyrrolo[2,3-d]pyrimidin-4-yl) -amino]-piperidin-1-yl}-3-oxo-propionitrile, or Opened in Brochure No. 04 / 052359 or Brochure No. 05 / 066156 Compounds shown; Sphingosine-1-phosphate receptor modulators, e.g. FTY7 20 (fingolimod), or in the brochure of International Publication No. 2005 / 000833 Disclosed compounds; immunosuppressant monoclonal antibodies, such as leukocyte receptors (e.g., MHC, CD2, CD3, CD4, CD7, CD8, CD25, CD28, CD40, C D45, CD52, CD58, CD80, CD86) or their ligands clonal antibodies; other immunomodulatory compounds, such as antibodies that bind at least one of the extracellular domains of CTLA4. Recombinant binding molecules or variants thereof, e.g., non-CTLA4 protein sequences, At least the extracellular portion of CTLA4 or a variant thereof, e.g., CTLA 4Ig (e.g., designated ATCC 68629) or a variant thereof, e.g., L EA29Y; adhesion molecule inhibitors, e.g., LFA-1 antagonist, ICAM-1 antagonist agonist or ICAM-3 antagonist, VCAM-4 antagonist, or VLA-4 antagonists; or chemotherapeutic agents, such as paclitaxel, gemcitabine, Cisplatinum, doxorubicin, or 5-fluorouracil; or an anti-infective agent. Further combination partners for the compounds of I) may be selected from: PI3 K inhibitors (e.g., pan, or alpha, beta, gamma, delta selective), TNF inhibitors agents, IL1 beta inhibitors, IL17 inhibitors, and inhibitors of the IL6 receptor or IL receptors.
[0099] In one embodiment, the present invention provides a method for treating a disease in a subject in need thereof, which is typically ameliorated by inhibition of BTK. A method for treating a disease or disorder, comprising administering to a subject in need thereof N-(3-(6-amino-5-( 2-(N-methylacrylamide)ethoxy)pyrimidin-4-yl)-5-fluoro- Crystalline form of 2-methylphenyl)-4-cyclopropyl-2-fluorobenzamide A therapeutically effective amount of Form A, Form B, or a combination thereof, preferably Form A, is administered alone. or in combination with one or more therapeutic agents.
[0100] In another embodiment, the present invention provides a method for treating a disease in a subject in need thereof, typically ameliorated by inhibition of BTK. and diseases or disorders that affect the immune system (e.g., inflammatory and autoimmune disorders, and inflammation of the lungs and airways). The method of treatment comprises administering to the subject a pharmaceutical composition described herein, either alone or in combination with relates to methods that include administering the compound in combination with one or more therapeutic agents.
[0101] In another embodiment, the present invention provides a method for treating a disease in a subject in need thereof, typically ameliorated by inhibition of BTK. and diseases or disorders that affect the immune system (e.g., inflammatory and autoimmune disorders, and inflammation of the lungs and airways). A method of treating a subject comprising administering to said subject a pharmaceutical combination as described herein. The present invention relates to a method comprising:
[0102] In one embodiment, the present invention relates to a method for treating a disease or disorder that is typically ameliorated by inhibition of BTK. For example, for the treatment of inflammatory and autoimmune disorders, and inflammation of the lungs and airways. N-(3-(6-amino-5-amino- -(2-(N-methylacrylamide)ethoxy)pyrimidin-4-yl)-5-fluoro Crystalline form of (2-methylphenyl)-4-cyclopropyl-2-fluorobenzamide (Form A, Form B, or a combination thereof, preferably Form A).
[0103] In yet another embodiment, the present invention relates to a method for treating a disease or condition that is typically ameliorated by inhibition of BTK. in the treatment of disorders (e.g., inflammatory and autoimmune disorders, and inflammation of the lungs and airways). N-(3-(6-amino-5-(2-(N-methylacrylamide)ethoxy) Pyrimidin-4-yl)-5-fluoro-2-methylphenyl)-4-cyclopropane The crystalline form of 2-fluorobenzamide (form A, form B, or a combination thereof, Preference is given to form A).
[0104] In yet another embodiment, the present invention relates to a method for treating a disease or condition that is typically ameliorated by inhibition of BTK. The present invention relates to N-(3-(6-amino-5-(2-(N-methylacetyl) arylamide)ethoxy)pyrimidin-4-yl)-5-fluoro-2-methylphenyl) Crystalline form of 4-cyclopropyl-2-fluorobenzamide (form A, form B, or Regarding these combinations, preferably form A) and one or more therapeutic agents: do.
[0105] In one embodiment, the present invention relates to a method of treatment, use, or method for use as described herein. The present invention relates to a compound, or a combination for use in a method for treating a disease that is typically ameliorated by inhibition of BTK. The disease or disorder is selected from inflammatory and autoimmune disorders, and inflammation of the lungs and airways. Related to the methods of treatment, uses, compounds for use, or combinations for use More specifically, diseases or disorders that are typically ameliorated by inhibition of BTK include those selected from the following: Selected: Autoimmune disorders, inflammatory diseases, allergic diseases, airway diseases, e.g., asthma and Chronic obstructive pulmonary disease (COPD), transplant rejection; antibody production, antigen presentation, cytokine production diseases in which lymphoid or lymphoid tissue formation is abnormal or undesirable; e.g., rheumatoid arthritis, Systemic onset juvenile idiopathic arthritis (SOJIA), gout, pemphigus vulgaris, idiopathic thrombocytopenic purpura Plaque disease, systemic lupus erythematosus, multiple sclerosis, myasthenia gravis, Sjogren's syndrome, autoimmune diseases Autoimmune hemolytic anemia, antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis, cryoglobulinemia thrombotic thrombocytopenic purpura, chronic urticaria (chronic idiopathic urticaria, induced urticaria), chronic Allergies (atopic dermatitis, contact dermatitis, allergic rhinitis), atherosclerosis Sclerosis, type 1 diabetes, type 2 diabetes, inflammatory bowel disease, ulcerative colitis, Crohn's disease, pancreatitis, thread Glomerulonephritis, Goodpasture's syndrome, Hashimoto's thyroiditis, Graves' disease, antibody-mediated graft rejection Acute, acute, and chronic graft-versus-host disease (AMR), B cell-mediated hyperacute rejection; thromboembolic disorders; myocardial infarction; angina pectoris; stroke; ischemic disorders; pulmonary embolism; hematopoietic organ Cancers of the body, including, but not limited to, multiple myeloma; leukemia; acute myeloid leukemia; chronic myeloma Myeloid leukemia; Non-Hodgkin's lymphoma; Lymphoma; True erythrocytic leukemia essential thrombocythemia; myelofibrosis with myeloid metaplasia; and Waldenstrom's disease Preferably, the disease or disorder that is typically ameliorated by inhibition of BTK is rheumatoid arthritis. chronic urticaria, preferably chronic idiopathic urticaria; Sjogren's syndrome, multiple sclerosis, or Asthma.
[0106] Crystalline form A described herein has been found to have advantageous properties.
[0107] Form A of the compound of formula (I) is the most stable form. Form A exhibits high levels of % RH was physically stable when exposed to high temperatures and during prolonged exposure to stressful conditions Form A can also be prepared in non-chlorinated solvents (e.g., solvents other than dichloromethane and chloroform). It is also stable as a suspension in water.
[0108] Due to its non-hygroscopic behavior, the physicochemical properties of Form A of the present invention are dependent on the relative humidity of the surrounding atmosphere. and thus allowing easier and more reliable storage of said pharmaceutical product comprising said Form A. In addition, crystalline form A is more resistant to harsh temperatures and therefore easier to store. and / or when exposed to humidity stress conditions or slurries in various solvents over time The crystalline structure of this crystalline form A is preserved even when the crystalline form is fused to the solid support.
[0109] Chloroform and dichloromethane solvents lead to the formation of modification B and / or modification C. I realized that.
[0110] Modification C is a metastable form because it can be heated at room temperature or at 50° C. This causes the organism to transform into Pervert B.
[0111] Modification B is stable up to 170°C, but above 170°C it transforms into modification A.
[0112] Pharmaceutical Compositions, Dosages, and Administration In one embodiment, the N-(3-(6-amino-5-(2-(N -Methylacrylamide)ethoxy)pyrimidin-4-yl)-5-fluoro-2-methyl The crystalline form of 4-cyclopropyl-2-fluorobenzamide was or a pharmaceutical composition, which also contains at least one pharma- ceutically acceptable excipient. and formulated into a pharmaceutical composition which often includes at least two or more pharma- ceutically acceptable excipients. Some suitable excipients are disclosed herein. Other excipients known in the art may be used without departing from the scope.
[0113] In some embodiments, the present invention provides a pharmaceutical composition comprising a compound of the present invention and a pharma- ceutically acceptable excipient. The present invention relates to a pharmaceutical composition comprising:
[0114] As used herein, the term "pharmaceutically acceptable excipient" refers to any excipient that is readily understood by those skilled in the art. Any and all solvents, carriers, diluents, dispersion media, coatings, surfactants agents, antioxidants, preservatives (e.g., antibacterial agents, antifungal agents, antioxidants), isotonicity agents, absorption delaying agents agents, salts, drug stabilizers, binders, additives, fillers, disintegrants, lubricants, sweeteners, flavors, colors and the like, and combinations thereof (e.g., Remington's s Pharmaceutical Sciences,18th Ed.Mack P See Rinting Company, 1990, pp. 1289-1329. Except insofar as any conventional excipient is incompatible with the active ingredient, it may be used in any therapeutic composition or pharmaceutical preparation. It should be understood that the use of any conventional excipient in the pharmaceutical compositions is contemplated by the present application. It is.
[0115] The pharmaceutical compositions are formulated for specific routes of administration, such as oral, parenteral, and rectal. In addition, the pharmaceutical compositions of the present invention can be formulated into solid forms (such as, but not limited to, capsules). In the form of a drug, the drug may be administered in the form of a drug in the form of a capsule, tablet, pill, granule, powder, or suppository, or in a liquid form (e.g., limited The pharmaceutical compositions may be formulated in any suitable form, including, but not limited to, a liquid solution, suspension, or emulsion. may be subjected to manipulation and / or may contain conventional inert diluents, lubricants, carriers, or buffers, as well as and adjuvants (e.g., solvents, preservatives, stabilizers, wetting agents, emulsifiers, buffers, etc.) It may include.
[0116] Typically, the pharmaceutical composition comprises a tablet containing the active ingredient together with at least one excipient. or a capsule, the excipient of which is a) Diluents, such as lactose, dextrose, sucrose, mannitol, sol bitol, cellulose, and / or glycine; b) Lubricants, such as silica, talc, stearic acid, its magnesium or calcium salts. um salts, and / or polyethylene glycol; In the case of tablets, c) Binders, such as magnesium aluminum silicate, starch paste, gelatin, tallow Gacant, methylcellulose, sodium carboxymethylcellulose, and / or poly Vinylpyrrolidone; Also listed, if necessary, d) Carriers, such as cosolvating agents (e.g., captisol, P an aqueous vehicle comprising glycerin, cyclodextrin, glyceryl stearate ... e) disintegrants, such as starch, agar, alginic acid or its sodium salt, or saccharides. foamy mixture; and / or f) Absorbents, colouring agents, flavouring agents and sweeteners Examples include:
[0117] Tablets may be film coated or enteric coated according to methods known in the art. It can be.
[0118] Preferably, the compound or composition is formulated for oral administration (e.g., tablets or or capsules), in any multi-dose form suitable for storage and / or administration of unit doses of the medicinal product. Examples of suitable packaging include sealed metal foils, unit dose containers (e.g. Packs include, but are not limited to, vials, blister packs, and strip packs. I can't.
[0119] Tablets may be prepared by mixing the active ingredient with non-toxic pharma- ceutically acceptable excipients which are suitable for the manufacture of tablets. These excipients may be, for example, inert diluents, such as calcium carbonate. , sodium carbonate, lactose, calcium phosphate, or sodium phosphate; granules and Disintegrants, such as corn starch or alginic acid; binders, such as starch, gelatin, or acacia; and lubricants such as magnesium stearate, stearic acid, The tablets are uncoated or have a coating that disintegrates in the gastrointestinal tract. and delayed absorption, thereby resulting in a sustained action over a longer period. For example, glyceryl monostearate or distearate are used to coat the A time delay material such as glyceryl stearate may be used. Formulations for oral use may contain the active ingredient The diluent is an inert solid diluent (e.g., calcium carbonate, calcium phosphate, or kaolin). ) or as a hard gelatin capsule in which the active ingredient is mixed with water or an oil medium. Softening agents that are mixed with oils (e.g., peanut oil, liquid paraffin, or olive oil) It may be provided as a gelatin capsule.
[0120] The present invention uses water as an active ingredient because water may accelerate the decomposition of certain compounds. Further provided are anhydrous pharmaceutical compositions and dosage forms comprising the compounds of the present invention.
[0121] Anhydrous pharmaceutical compositions and dosage forms of the invention contain anhydrous or low moisture containing ingredients and low moisture conditions. Alternatively, low humidity conditions may be used to prepare anhydrous pharmaceutical compositions, and their anhydrous nature may be utilized. Anhydrous compositions can be stored to maintain their original purity. Thus, anhydrous compositions can be stored to prevent exposure to water. Using known materials, the composition is preferably capable of being included in a suitable formulary kit. Examples of suitable packaging include hermetically sealed metal foils, plastic, unit dose containers (e.g., Examples of suitable packaging materials include vials, blister packs, and strip packs. Not limited.
[0122] The present invention reduces the rate at which the compounds of the present invention as active ingredients will decompose. Further provided are pharmaceutical compositions and dosage forms that contain one or more of such drugs. Ascorbic acid, pH buffer, salt buffer, etc. (referred to as "stabilizers" in the specification) Antioxidants include, but are not limited to:
[0123] The pharmaceutical composition or combination of the present invention is administered in an amount of about 1 to 100 mg / kg to a subject weighing about 50 to 70 kg. 0 mg of active ingredient, or about 1-500 mg, or about 1-250 mg, or about 1- 150 mg, or approximately 0.5 to 100 mg, or approximately 1 to 50 mg of active ingredient Preferably, the pharmaceutical composition or combination of the present invention is administered in an amount of about 10 mg, about The compound, pharmaceutical composition, or combination thereof may be a unit dose of about 25 mg, or about 50 mg. The combined therapeutically effective dose or amount will vary depending on the species, weight, age, and individual condition of the subject, The nature of the disorder or disease and its severity will depend on the physician, clinician, or other person of ordinary skill in the art. or a veterinarian may determine that a particular condition is present that is necessary to prevent, treat, or inhibit the progression of a disorder or disease. The effective amount of each of the active ingredients can be readily determined.
[0124] The dosage characteristics cited above are advantageously used in mammals (e.g. mice, rats, dogs, In vitro tests and The compounds of the present invention can be demonstrated by in vitro solution ( For example, in vivo, enterally, parenterally, advantageously intravenously, preferably in the form of an aqueous solution. The in vitro dosage may be administered intravenously, for example, as a suspension or as an aqueous solution. , about 10-3 Molar ~ 10 -9 The therapeutically effective in vivo The amount ranges from about 0.1 to 500 mg / kg or about 1 to 100 mg / kg depending on the route of administration. Preferably, the therapeutically effective amount in vivo is from about 10 mg to about 10 mg per day. 200 mg, for example, about 10 mg, about 20 mg, about 25 mg, about The range is about 35 mg, about 50 mg, about 100 mg, or about 200 mg. A therapeutically effective amount in vivo is about 10 mg, about 35 mg, about 50 mg, or Preferably, the therapeutically effective amount in vivo is selected from about 100 mg. Selected from about 10 mg, about 25 mg, about 50 mg, or about 100 mg, twice daily.
[0125] In other embodiments, at least one crystalline form according to the embodiments described herein above. (e.g., Form A, Form B, or a mixture thereof, preferably Form A) and at least one and a pharma- ceutically acceptable carrier are provided.
[0126] Thus, in one embodiment of the present disclosure, N-(3-(6-amino-5-(2-(N-methyl (Ethoxy)pyrimidin-4-yl)-5-fluoro-2-methylphenyl The crystalline form of (form A or form B)-4-cyclopropyl-2-fluorobenzamide Preferably, form A) is provided in substantially phase-pure form. N-(3-(6-amino-5-(2-(N-methylacrylamide)ethoxy)pyrimidinyl) (4-fluoro-2-methylphenyl)-5-fluoro-2-methylphenyl This crystalline form of orobenzamide (Form A or Form B) can be used to administer one or more drugs Pharmaceutical compositions can be prepared which may further include a physiologically acceptable excipient.
[0127] combination: The crystalline form of the compound of formula (I) of the present invention (e.g., Form A or Form B, or any combination thereof) Can the mixture, preferably form A), be administered simultaneously with one or more other therapeutic agents? The crystals of the present invention may be administered before or after the therapeutic agent. The forms may be administered separately by the same or different routes of administration, or may be administered in the same dosage form as other agents. The compounds may be administered together in a pharmaceutical composition.
[0128] The crystalline forms of the compounds of formula (I) may be administered as the sole active ingredient or in combination with other drugs. It may be administered in conjunction with (eg, as an adjuvant to) other drugs, Examples of such agents include immunosuppressants or immunomodulators, or other anti-inflammatory agents (e.g. For example, acute or chronic rejection of allografts or xenografts, or inflammatory disorders or or anti-inflammatory agents for the treatment or prevention of autoimmune disorders, or chemotherapeutic agents (e.g., For example, the crystalline forms of the compound of formula (I) may be used in combination with Calcineurin inhibitors, such as cyclosporin A or FK 506; mTOR Inhibitors, such as rapamycin, 40-O-(2-hydroxyethyl)-rapamycin, CCI779, ABT578, AP23573, AP23464, AP23675, AP 23841, TAFA-93, Biolimus-7, or Biolimus-9; immunosuppression Ascomycins having anti-inflammatory properties, such as ABT-281, ASM981, etc.; roid;cyclophosphamide;azathioprene;methotrexate;leflunomide;mizo Livin; Mycophenolic acid or mycophenolate salt; Mycophenolate mofetil; 15-Deoxyspergualin, or its immunosuppressive homologues, analogues, or immunosuppressants immunosuppressive derivatives; PKC inhibitors, e.g., those described in WO 02 / 38561 or or PKC inhibitors disclosed in the pamphlet of US Pat. No. 03 / 82859, e.g. The compound of Example 56 or 70; a JAK3 kinase inhibitor, for example N-benzyl-3,4 -Dihydroxy-benzylidene-cyanoacetamide α-cyano-(3,4-dihydro N-Benzylcinnamamide (Tyrphostin AG 490), Propylene glycol Digiosin 25-C (PNU156804), [4-(4'-hydroxyphenyl)- Amino-6,7-dimethoxyquinazoline](WHI-P131), [4-(3'-bromo -4'-hydroxyphenyl)-amino-6,7-dimethoxyquinazoline](WHI- P154), [4-(3',5'-dibromo-4'-hydroxyphenyl)-amino- 6,7-dimethoxyquinazoline]WHI-P97, KRX-211, free form or drug A physiologically acceptable salt form (e.g., the monocitrate salt) (also called CP-690,550) 3-{(3R,4R)-4-methyl-3-[methyl-(7H-pyrrolo[2,3-d] pyrimidin-4-yl)-amino]-piperidin-1-yl}-3-oxo-propionyl Trill, or International Publication No. WO 04 / 052359 or WO 05 / 0661 Compounds disclosed in Pamphlet No. 56; Sphingosine-1-phosphate receptor Modulators, such as FTY720 (fingolimod), or WO 2005 / 000 compounds disclosed in brochure 833; immunosuppressant monoclonal antibodies, e.g. Leukocyte receptors (e.g., MHC, CD2, CD3, CD4, CD7, CD8, CD25, CD28, CD40, CD45, CD52, CD58, CD80, CD86) or monoclonal antibodies against the ligand of CTLA4; other immunomodulatory compounds, e.g. A recombinant binding molecule having at least a portion of the extracellular domain or a variant thereof, e.g., At least the extracellular portion of CTLA4 or a variant thereof bound to the CTLA4 protein sequence. Variants such as CTLA4Ig (designated, for example, as ATCC 68629) or or mutants thereof, e.g., LEA29Y; adhesion molecule inhibitors, e.g., LFA-1 antagonists; antagonist, ICAM-1 antagonist or ICAM-3 antagonist, VCAM-4 antagonist or a VLA-4 antagonist; or a chemotherapeutic agent, e.g., paclitaxel cisplatinum, doxorubicin, or 5-fluorouracil or an anti-infective agent. Further combination partners for the compounds of formula (I) include PI3K inhibitors (e.g., pan, or alpha, beta, gamma, delta selective), TNF inhibitors, IL1 beta inhibitors, IL17 inhibitors, and IL6 receptor or is an inhibitor of IL receptors.
[0129] Medical kit In one embodiment, the present invention provides a kit comprising two or more separate pharmaceutical compositions, At least one of these pharmaceutical compositions contains a crystalline form of the compound of formula (I) (Form A, Form B, or a mixture thereof, preferably form A). The kit may include a container, a divided bottle, or a divided foil pouch, etc., for dispensing the composition. An example of such a kit includes tablets, capsules, and The blister pack is one such type of pack commonly used for packaging medical supplies and the like.
[0130] The kits of the present invention may be packaged in separate packages for administration in various dosage forms (e.g., oral and parenteral). To administer the compositions at different dosage intervals or to titrate the separate compositions relative to each other. To aid in compliance, the kits of the invention typically include instructions regarding administration. Includes instructions for using the
[0131] In the combination therapy of the present invention, the crystalline forms of the compound of formula (I) (i.e., Form A, Form B, or mixtures thereof, preferably form A), together with other therapeutic agents, in the same or different manufacturing process. Further, the crystalline form of the compound of formula (I) and and (i) administering the combination product to a physician (e.g., a compound of formula (I) (ii) in the case of a kit containing a crystalline form of the compound and another therapeutic agent, by the physician immediately prior to administration; (iii) by administering to the patient himself / herself, e.g., a compound of formula (I), During sequential administration of a crystalline form of and another therapeutic agent, they may be combined into a combination therapy.
[0132] Thus, the present invention relates to a method for treating diseases that are ameliorated by inhibition of BTK (e.g., autoimmune diseases, anti-inflammatory diseases, etc.). The crystalline forms described herein (i.e., pulmonary diseases, respiratory diseases) can be used to treat i.e. the use of Form A, Form B or a mixture thereof, preferably Form A), The medicament is prepared for administration together with another therapeutic agent. In addition, the inhibition of BTK is effective in treating diseases that can be alleviated by the inhibition of BTK (e.g., autoimmune diseases, anti-inflammatory diseases, respiratory diseases, etc.). The use of a therapeutic agent for treating a disease of the nervous system (disease of the nervous system), which agent is a compound of formula (I) The present invention also provides the use of a crystalline form of
[0133] The present invention also provides a compound of formula (I) for use in a method for treating a disease ameliorated by BTK inhibition. I) in a crystalline form (i.e., form A, form B, or a mixture thereof, preferably is Form A), and the crystalline form of the compound of formula (I) is prepared for administration together with another therapeutic agent. The present invention also provides a crystalline form of BTK that has been shown to be effective in treating diseases that are ameliorated by inhibition of BTK. Another immunotherapeutic agent for use in the method of treating, said other therapeutic agent being of formula (I) Also provided is an additional immunotherapeutic agent that is prepared for administration together with the crystalline form of the compound. The present invention also provides a compound of formula (I) for use in a method for treating a disease ameliorated by inhibition of BTK. A crystalline form of a compound of formula (I) which is administered in combination with another therapeutic agent. The present invention also provides a crystalline form of BTK that is capable of treating diseases that are ameliorated by inhibition of BTK. a further therapeutic agent for use in the method of administering to said subject a subject the therapeutic agent being a compound of formula (I) Also provided is an additional therapeutic agent that is administered together with the crystalline form.
[0134] The present invention also relates to methods for treating diseases that are ameliorated by inhibition of BTK (e.g., autoimmune diseases, anti-inflammatory Use of a crystalline form of the compound of formula (I) for treating a variety of conditions, including diseases of the respiratory system, comprising Also provided is the use, where the patient has already been treated (eg, within 24 hours) with another therapeutic agent. The present invention also relates to the treatment of diseases that are ameliorated by inhibition of BTK (e.g., autoimmune diseases, anti-inflammatory diseases, etc.). The present invention relates to a method for treating a patient suffering from a pulmonary disease (pulmonary disease, respiratory disease) using another therapeutic agent, the method comprising administering to the patient a compound of formula (I) Uses are also provided in which the patient has already been treated (eg, within 24 hours) with a crystalline form of the compound.
[0135] Crystal form N-(3-(6-amino-5-(2-(N-methylacrylamide)ethoxy) pyrimidin-4-yl)-5-fluoro-2-methylphenyl)-4-cyclopropyl- Preparation of 2-fluorobenzamide: Crystalline forms can be identified by various methods (e.g., crystallization or recrystallization from a suitable solvent, sublimation, melting, etc. growth from solids, solid-state transformation from another phase, crystallization from supercritical fluids, and jet atomization) As a technique for crystallization or recrystallization of the crystalline form from a solvent or solvent mixture. , for example evaporation of the solvent, lowering the temperature of the solvent or solvent mixture, supersaturation of the solvent with molecules and / or salts Crystal seeding of the mixture, freeze-drying of the solvent mixture, and addition of an anti-solvent (counter-solvent) to the solvent mixture The addition of a countersolvent as described herein may be used. Exemplary methods for preparing the crystalline forms are described in detail below.
[0136] Drug crystals (including polymorphs), preparation methods, and characterization of drug crystals are described in S solid-state chemistry of drugs,SR Byrn, R.R. Pfeiffer, and J.G. Stowell, 2 nd Edit on, SSCI, West Lafayette, Indiana (1999) It is being done.
[0137] For solvent-based crystallization techniques, the choice of solvent typically depends on one or more factors (e.g. The solvent combination depends on the solubility of the compound, the crystallization technique, and the vapor pressure of the solvent. For example, a compound may be dissolved in a first solvent to obtain a solution, followed by the addition of an anti-solvent. The antisolvent can reduce the solubility of the compound in the solution and cause crystals to form. A solvent is a solvent in which the compound has low solubility.
[0138] One method for preparing crystals is to suspend and / or slurried the compound in a suitable solvent. The slurry may be heated to facilitate dissolution. As used herein, solubility in water is defined as the concentration of water in a saturated solution of a compound at a given temperature. and a saturated solution which may also contain additional amounts of this compound in order to obtain a heterogeneous mixture of the solvent. This is also called a suspension.
[0139] Seed crystals may be added to any crystallization mixture to promote crystallization. Seeding is used to It is therefore possible to control the growth of polymorphs of the desired product or to control the particle size distribution of the crystalline product. The amount of seeds that can be calculated is given in, for example, “Programmed Cooling of Batch Crystallizers,” J. W. Mullin and J. Nyvlt, Chemical Engineering Science,1971,26,369 -377, the size of the available seeds and the location of the average product particles Generally, to effectively control the growth of crystals in a batch, Small seeds are required. Small seeds are obtained by sieving large crystals, crushing, and Crystal powders can be produced by micronization or by microcrystallization of a solution. Crushing or micronization can result in a change in the crystallinity of the desired crystalline form (i.e., to amorphous or another polymorph). Care must be taken to prevent this from happening.
[0140] The cooled crystallization mixture can be filtered under vacuum and the isolated solid can be dissolved in a suitable solvent such as cold recrystallization solvent. The desired crystalline form can be obtained by washing with an appropriate solvent and drying under a nitrogen purge. The isolated solids are analyzed using a suitable spectroscopic or analytical technique (e.g., solid-state nuclear magnetic resonance, differential scanning thermography). NMR spectroscopy, X-ray powder diffraction, or the like) to determine the formation of the desired crystalline form of the product. The crystal form obtained may be determined based on the weight of compound originally used in the crystallization procedure. Typically, the isolated yield is greater than about 70% by weight, and preferably greater than 90% by weight. The product is produced in isolated yield amounts. If necessary, the product can be co-ground or meshed. The product may be passed through a screen to remove lumps.
[0141] Alternatively, the crystalline form may be N-(3-(6-amino-5-(2-(N-methylacrylamide) ethoxy)pyrimidin-4-yl)-5-fluoro-2-methylphenyl)-4-cyclohexyl From the reaction medium of the final process for preparing chloropropyl-2-fluorobenzamide This can be achieved, for example, by preparing the compound in a solvent or mixture of solvents in a final process step. This product is N-(3-(6-amino-5-(2-(N-methylacrylamide) )Ethoxy)pyrimidin-4-yl)-5-fluoro-2-methylphenyl)-4-cyclohexyl A solvent or mixture of solvents is used in which 2-propyl-2-fluorobenzamide can be crystallized. In addition, crystalline forms can be obtained by distillation or solvent addition techniques. can be done.
[0142] In addition to the methods briefly discussed below, any of the materials described herein may be used in combination with other methods. It should be understood that a variety of analytical methods may be used for characterization.
[0143] The following non-limiting examples are illustrative of the present disclosure. EXAMPLES
[0144] Example 1: Preparation of anhydrous crystalline form A [ka] N-(3-(6-amino-5-(2-(methylamino)ethoxy)pyrimidin-4-yl) (phenyl)-5-fluoro-2-methylphenyl)-4-cyclopropyl-2-fluorobenzyl Amide (Intermediate 10 disclosed in WO 2015 / 079417) ) and sodium carbonate were suspended in ethyl acetate and heated to 50°C. A solution of acrylic anhydride in ethyl acetate (20% w / w) was added. The reaction mixture was stirred for 5 The mixture was stirred at 0° C. for about 30 minutes. After the addition of water, the reaction mixture was stirred at 65° C. for about 30 minutes. The phases are then separated at 60°C and the aqueous phase is removed. The organic phase is diluted with 0.05M The organic phase was washed with water and the aqueous phase was removed at 60° C. The final organic phase was treated by low particle filtration. The distillation was reduced at an internal temperature of 60°C. A portion of the solvent mixture was removed under reduced pressure while ethyl acetate was added to reduce the solvent level. The water content was kept approximately constant. This reduced the water content. (Optionally, the solution was diluted with vinegar.) (Add a seed suspension of Form A in ethyl acetate). The suspension is stirred for at least 15 minutes. Afterwards, further distillation at an internal temperature of 60° C. was carried out under reduced pressure to remove the solvent mixture. An aliquot was removed and ethyl acetate was added at the same time to keep the solvent level approximately constant.
[0145] The suspension was stirred at 60° C. for 30 min, cooled to 30° C. in 200 min, and then cooled to 30° C. The mixture was stirred at rt for 30 min. At an internal temperature of 30° C., a final distillation was carried out under reduced pressure. Ethyl acetate was added to keep the solvent level approximately constant. Stirring at 30° C. for 120 min. The suspension was then cooled to 0°C within 300 min and stirred at 0°C for at least 240 h. The product is isolated by centrifugation and the filter cake is washed twice with ethyl acetate. The resulting wet product was dried on trays in a drying oven at 40° C. under vacuum. Crystal form A was obtained. Modification A was characterized by HR-XRPD, LCMS, TGA, and DSC. Lactolized.
[0146] Example 2: Preparation of anhydrous crystalline form C Modification A (Example 1) was suspended in dichloromethane at 50° C. for 3 days. The suspension was filtered through a Buchner filter. The solid was collected by filtration and allowed to stand at room temperature overnight. The mixture was dried at 40° C. under vacuum (200 mbar) to give modification C. Modification C was stored at −20° C. This prevented further changes.
[0147] Example 3: Preparation of anhydrous crystalline form B Modification C (Example 2) was left at room temperature and its transformation into modification B was monitored by HR-XRPD. This transformation was complete after 5 days.
[0148] Modifications B and C were characterized by HR-XRPD, LCMS, TGA, and DSC. It was.
[0149] Example 4: High-resolution powder X-ray diffraction The solid was finely ground in a mortar with a pestle. The compound was then crushed into a powder using an 8 mm boron glass knife. A capillary (0.3 mm diameter) was filled and carefully placed in the diffractometer.
[0150] The Bruker D8 Advance system equipped with the LynxEye solid-state detector The HR-XRPD patterns were collected at 296 K. The radiation used to collect this data was The radiation was CuKα1 (λ = 1.54056 Å) monochromated by a germanium crystal. Diffraction data were collected in the range 4-50° 2θ for modification A and 100° 2θ for modifications B and C. The data were collected in the range of 3 to 41.5° 2θ.
[0151] [Table 1]
[0152] [Table 2]
[0153] [Table 3]
[0154] Example 5: Differential Scanning Calorimetry (DSC) Melting characteristics were obtained from DSC thermograms and measured using a heat flux DSC822e instrument (Mettler The data was recorded using a 100mV 10 ... A small piece of indium (melting point 156.6°C; ΔH = 28.45 J / g) was used to measure the temperature and entropy. The samples were packed in standard 40 μl aluminium pans and pinched. The holes are opened or sealed and heated at 2°C / min, 5°C / min, 10°C / min, or 20°C / min. The sample was heated in the DSC from -20°C to 300°C at a flow rate of 50 ml / min during the measurement. Drying at N 2Gas was used to purge the DSC instrument.
[0155] Cyclic DSC was performed on the same instrument. Samples were placed in standard 40 μl aluminum pans. The sample was sealed, pinhole drilled, and heated in a DSC from 20°C to 195°C, and from 195°C to - The mixture was cooled to 20°C and then heated again from -20°C to 300°C. The heating and cooling rates were The temperature measurement accuracy of the sample by this method is within ±1°C. Heat can be measured within a relative error of about ±5%.
[0156] DSC measurements of modifications A, B, and C were performed at various heating temperatures in open and sealed pans. The reaction was carried out at a rate of -20 to 300°C.
[0157] DSC traces recorded in an open pan for modifications A, B, and C, respectively. The onset temperatures of exothermic / endothermic events observed in the DSC traces are reported in Figures 2, 5, and 8. The degrees are reported in Tables 4, 5, and 6, respectively.
[0158] In both sets of DSC measurements, the thermal expansion to higher temperatures was achieved by increasing the heating rate. A general shift in the events was observed, as was a spreading of the events.
[0159] The DSC curves of modification A are in the range 193–199 in both open and closed pans. The onset melting temperature was 95 °C. DSC measurement of modification B showed an endotherm at 170-180 °C. The exothermic event could be associated with the melting of modification B and recrystallization to A.
[0160] In the DSC trace of modification C, the presence of an endothermic / thermal event at 170–180 °C indicates that heating This confirmed that metamorph C was transformed into metamorph B.
[0161] [Table 4]
[0162] [Table 5]
[0163] [Table 6]
[0164] Example 6: Thermogravimetric Analysis (TGA): The mass loss due to the loss of solvent or water from the crystals was measured using TGA / SDTA (single differential thermal analysis). The solubility of the cellulose acetate was determined by TGA / DSC (thermogravimetric analysis combined with mass spectrometry) and TGMS (thermogravimetric analysis combined with mass spectrometry). 3+ STARe system (Mettler-Toledo GmbH, Switzerland) By monitoring the sample weight during heating in a 1000 sq. m. rand, a weight vs. temperature curve was obtained. The TGA / DSC 3+ was measured with samples of indium and aluminum at different temperatures. The sample (approximately 2 mg) was weighed into a 100 μL aluminum crucible. A pinhole was drilled in the seal and the crucible was heated to 25° C. at a heating rate of 10° C. / min. The mixture was heated in a TGA at 300 °C for 2 h. Dry N 2 Gas was used to purge the TGA samples. The gas coming out of the sintering chamber was analyzed by a mass spectrometer Omnistar GSD 301 T2 (Pfeif The analysis was performed at FerroVacuum GmbH, Germany. It is an analyzer that analyzes mass over a temperature range of 0 to 200 amu. It reports temperature in degrees Celsius (℃). and report the weight loss as a percentage.
[0165] TGA / SDTA analysis of modification A (Figure 3) shows a mass loss of 0.3% in the range 40–200 °C. A small amount of 1 in the SDTA curve was evident, indicating that modification A was anhydrous. The endothermic peak near 90°C could be attributed to the melting of the compound. Decomposition occurred.
[0166] Figure 3. TGA / SDTA analysis of modification A (heating rate of 10 °C / min). Mass loss of 0.3%. was recorded in the range 40-200 °C. Thermal decomposition occurred above 240 °C.
[0167] TGA / SDTA analysis of modification B (Figure 6) shows a mass loss of 0.2% in the range 40–160 °C. Therefore, modification B was anhydrous. The events occurring at 1000° C. are the melting of modification B and its recrystallization into modification A, followed by the final crystallization of modification A. Thermal decomposition occurred above 240°C.
[0168] Figure 6. TGA / SDTA analysis of modification B (heating rate of 10 °C / min). Mass loss of 0.2%. was recorded in the range 40-160 °C. Thermal decomposition occurred above 240 °C.
[0169] TGMS analysis of modification C (Fig. 9) reveals a mass loss of 0.01% in the range 40–150 °C. This indicates that modification C is an anhydrous crystalline phase. occurred.
[0170] Figure 9. TGA / SDTA (20A) and TGMS (20B) analysis of modification C (10 °C / min A mass loss of 0.01% was recorded in the range 40-150°C. Above 240°C Thermal decomposition occurred.
[0171] Example 4: Comparison of physicochemical stability Metamorphs A, B, and C were exposed to the following stress conditions: 80°C in a closed vial for 1 month; 80℃ / 75%RH in open vials for 1 month: 100°C in a closed vial for 3 days.
[0172] The solid was then analyzed by HR-XRPD, TGMS, and HPLC assays to determine: Potential solid phase changes, loss on drying, and chemical purity were evaluated.
[0173] Upon completion of the stability studies, all solids were analyzed by HR-XRPD, TGMS, and HPLC. The results of the physicochemical stability tests are reported in Table 7.
[0174] HPLC conditions Auto sampler temperature: 15℃ Column: Waters Sunfire C18 (100 × 4.6 mm; 3.5 μm). Column temperature: 35℃ Flow cell: 10mm path Gradient: Mobile phase A: 0.1% TFA in water Mobile phase B: 0.1% TFA in acetonitrile Flow rate: 1.0ml / min
[0175] [Table 7]
[0176] Run Time: 11 minutes
[0177] [Table 8]
[0178] After exposure to 80°C for 1 month and 100°C for 3 days, modification C was The XRPD patterns of modifications A and B did not change. In contrast, Metamorph C transformed into transformation B under all three test conditions.
[0179] TGMS analysis did not show any significant moisture absorption, therefore the solid was not hygroscopic.
[0180] The chemical purity of the samples was demonstrated within 3 days or 1 month as indicated by recovery values approaching 100%. The results showed that the solubility of the solubility-containing cellulose in the cellulose membrane was not affected by exposure to high temperatures and high RH levels.
[0181] Example 5: Hygroscopicity test Moisture absorption of pervert A The hygroscopicity of modification A was determined by exposing the solid material to 80% and 92% RH at 25°C for 24 hours. The solids were then analyzed by HT-XRPD to determine any changes in crystalline phase. was evaluated and analyzed by TGMS to determine moisture uptake.
[0182] Modification A was physically stable after exposure to 80 and 92% RH for 24 hours. TGMS analysis revealed a mass loss of 0.2% for both samples. , modification A could be considered as non-hygroscopic.
[0183] Moisture sorption isotherms of modification A at 25°C and 40°C Dynamic Vapor Sorption (DVS): Moisture sorption isotherms are calculated using surface measurements. The data were collected using a DVS-1 system from T Systems (London, UK). The sample size was 5-10 mg of solid material. The relative humidity profile was measured in one step. With a 10% increase in RH level per step, the change was 40→0→95→0→95→40%. Weight Equilibration times were set at a minimum of 60 minutes and a maximum hold time of 6 hours per relative humidity step. and dm / dt was 0.002% / min.
[0184] Dynamic vapor sorption (DVS) measurements were performed over a 40% RH profile with 10% RH steps. →0→95→0→95→40% was carried out for modification A at 25°C and 40°C.
[0185] Modification A showed no significant water vapor uptake at both 25°C and 40°C. 95% At RH, the highest mass changes were 0.4% and 0.3% at 25°C and 40°C, respectively. The sorption and desorption cycles are reversible, and DVS measurements showed no signs of hydrate formation. The solid recovered after DVS measurement remained as modification A.
[0186] DVS measurements of metamorphs B and C DVS measurements performed on metamorphs B and C revealed similar results to those collected for metamorph A. Results were obtained. Both crystalline phases showed no significant water vapor uptake. 95%R The highest mass gain recorded for H was 0.3% for both phases.
[0187] The XRPD pattern of modification B did not change after DVS measurement. In contrast, the D The solid recovered after VS measurements was probably due to the spontaneous conversion of modification C to B at 25 °C. The result was a mixture of modifications B and C.
[0188] Example 5: Stability in Solvents Stability of modification A in solvents Suspensions of modification A were prepared in 23 selected solvents and incubated at room temperature (RT) for 4 weeks. The mixture was allowed to equilibrate for 2 weeks at 50° C. Upon completion of the equilibration period, the solid was transferred to the liquid phase. The product was isolated from the 1,000 sintered solids, dried under ambient conditions and under vacuum (5 mbar / 50 °C) and analyzed by HT-XRPD. Analyzed.
[0189] If the suspension has dissolved, evaporate under vacuum (first at 200 mbar / RT, then at 5 The solvent was removed by evaporation under the same conditions (at 1000 rpm, 500 rpm, 1000 rpm). The liquid phase was also evaporated under the same conditions. The solid was analyzed by HT-XRPD.
[0190] Experimental details and results of solvent equilibration experiments performed at RT and 50° C. are shown in Tables 8 and 9, respectively. 9.
[0191] [Table 9]
[0192] [Table 10]
[0193] Stability of modifications B and C in solvents Suspensions of modifications B and C were prepared in 15 selected solvents and incubated at room temperature for 2 weeks. The solution was then equilibrated at 50°C for one week. At the end of the equilibration period, the solid was removed from the liquid phase. The mixture was isolated from the solids, dried under ambient conditions and under vacuum (5 mbar / 50 °C) and analyzed by HT-XRPD. Analyzed.
[0194] If the suspension has dissolved, evaporate under vacuum (first at 200 mbar / RT, then at 5 The solvent was removed by evaporation under the same conditions (at 1000 rpm, 500 rpm, 1000 rpm). The liquid phase was also evaporated under the same conditions. The solid was analyzed by HT-XRPD.
[0195] The experimental details and results of the solvent equilibration experiments carried out at RT and 50°C for modification B are shown below. These are reported in Tables 10 and 11, respectively.
[0196] The experimental details and results of the solvent equilibration experiments carried out at RT and 50 °C for modification C are shown below. These are reported in Tables 12 and 13, respectively.
[0197] [Table 11]
[0198] [Table 12]
[0199] [Table 13]
[0200] [Table 14]
[0201] Example 6: Stability under simulated granulation experiments The granulation solvent was added to polymorphic Form A until the solid was sufficiently wetted. The suspension was then cooled with each addition. The suspension was stirred with a Vortex in between. The suspension was dried under vacuum. The remaining solid form The crystallinity was analyzed by XRPD and / or DSC. The granulation solvents tested were water, ethanol, and ethanol. The alcohols were ethanol, 2-propanol, acetone, and benzyl alcohol. was not observed.
[0202] Example 7: Stability under compression 100-300 mg of polymorphic form A was pressurized in a hydraulic press (plate diameter 13 mm) for 1 The samples were then analyzed by XRPD and DSC to determine the amount of condensation that occurred. The analysis revealed that the substance was unchanged. .
[0203] It has been discovered that modification A of compound of formula (I) is the most stable form. Metamorph A occurs when exposed to high levels of %RH and when exposed to prolonged stress conditions. Modification A was stable under compression and granulation simulation experiments. Modification A was obtained by removing chlorinated solvents such as chloroform and dichloromethane or by removing 50% Mixtures of solvents containing more than vol. % chlorinated solvents (e.g., dichloromethane and / or chloroform) It is stable in most solvents except for the above-mentioned compounds.
[0204] Chlorinated solvents such as chloroform and dichloromethane induce the formation of modifications B and C. I realized that I would be woken up. Both modifications B and C are metastable forms, since modification C is stable at room temperature or at 50 When heated at 170°C, it changes to modification B, which changes to modification A at temperatures above 170°C. It is.
Claims
1. 7.8±0.2 when measured at a temperature of about 25° C. and an X-ray wavelength λ of 1.5405 Å °2θ, 9.2±0.2°2θ, 12.0±0.2°2θ, 13.6±0.2°2θ, 1 5.6±0.2°2θ, 16.0±0.2°2θ, 17.8±0.2°2θ, 18.3± 0.2°2θ, 18.7±0.2°2θ, 19.2±0.2°2θ, 19.9±0.2° 2θ, 22.1±0.2°2θ, 23.4±0.2°2θ, 23.9±0.2°2θ, 2 4.8±0.2°2θ, 25.2±0.2°2θ, 25.5±0.2°2θ, 27.2± 1 with respect to 2θ selected from the group consisting of 0.2° 2θ, and 29.6±0.2° 2θ or Compound N-(3), characterized by an X-ray powder diffraction pattern including a plurality of representative peaks. -(6-amino-5-(2-(N-methylacrylamide)ethoxy)pyrimidine-4- 5-fluoro-2-methylphenyl)-4-cyclopropyl-2-fluorophenyl Crystalline forms of azamide.
2. The X-ray diffraction spectrum is substantially identical to the X-ray powder diffraction spectrum shown in FIG. The crystalline form of claim 1.
3. Differential thermogravimetry measured by differential scanning calorimetry (DSC) with a heating rate of 10° C. / min.
1. The profile includes a single endothermic peak with an onset of about 194° C. The crystalline form described in
4. The differential scanning calorimetry (DSC) thermogram is substantially identical to that shown in FIG. The crystalline form of claim 1.
5. As determined by thermogravimetric analysis, the decomposition point is greater than 240° C. and the weight loss when dried is The crystalline form of claim 1, wherein the minimum is about 0.3% in the range of 40 to 200°C.
6. The thermogravimetric analysis (TGA) diagram is substantially the same as that shown in FIG.
1. The crystalline form described in
7. The crystalline form of any one of claims 1 to 6, consisting essentially of Form A.
8. The method according to any one of claims 1 to 6, wherein the form is Form A in a substantially phase pure form. The crystal morphology of the compound.
9. 5.9±0.2° C., measured at a temperature of about 25° C. and an X-ray wavelength λ of 1.5405 Å. θ, 6.7±0.2°2θ, 7.8±0.2°2θ, 8.3±0.2°2θ, 11.1± 0.2°2θ, 12.1±0.2°2θ, 12.6±0.2°2θ, 13.0±0.2° 2θ, 13.3±0.2°2θ, 14.8±0.2°2θ, 15.8±0.2°2θ, 1 6.4±0.2°2θ, 17.6±0.2°2θ, 19.5±0.2°2θ, 20.2± 0.2°2θ, 20.6±0.2°2θ, 20.9±0.2°2θ, 21.6±0.2° 2θ, 22.3±0.2°2θ, 23.3±0.2°2θ, 24.0±0.2°2θ, 2 4.9±0.2°2θ, and 25.3±0.2°2θ The compound is characterized by an X-ray powder diffraction pattern including one or more representative peaks. N-(3-(6-amino-5-(2-(N-methylacrylamide)ethoxy)pyrimidinyl 5-fluoro-2-methylphenyl)-4-cyclopropyl-2-fluorophenyl Crystalline forms of orobenzamide.
10. The X-ray diffraction spectrum is substantially identical to the X-ray powder diffraction spectrum shown in FIG.
10. The crystalline form of claim 9.
11. Differential thermogravimetric profile measured by differential scanning calorimetry with a heating rate of 10° C. / min. The endothermic peak begins at about 170° C. (corresponding to the melting of modification B) and at about 175° C. (corresponding to the melting of modification A). An exothermic peak beginning at about 194° C. (corresponding to the recrystallization of modification A) and a 10. The crystalline form of claim 9, comprising an endothermic peak beginning at .
12. The differential scanning calorimetry (DSC) thermogram is substantially identical to that shown in FIG.
10. The crystalline form of claim 9.
13. As determined by thermogravimetric analysis, the decomposition point is greater than 240° C. and the weight loss when dried is The crystalline form of claim 9, wherein the minimum is about 0.2% in the range of 40 to 160°C.
14. The thermogravimetric analysis (TGA) diagram is substantially the same as that shown in FIG.
9. The crystalline form according to claim 9.
15. 15. The crystalline form of any one of claims 9 to 14, consisting essentially of form B.
16. 15. The method according to claim 9, wherein the form is a substantially phase-pure form B. The crystal morphology of the compound.
17. 10. A pharmaceutical composition comprising the crystalline form of claim 1 and a pharma- ceutically acceptable carrier.
18. 10. A pharmaceutical composition comprising the crystalline form of claim 9 and a pharma- ceutically acceptable carrier.
19. A method according to any one of claims 1 to 16 for the preparation of a medicament for the treatment of a disorder which is ameliorated by the inhibition of BTK. The N-(3-(6-amino-5-(2-(N-methylacrylamide)) according to any one of claims 1 to 5, Ethoxy)pyrimidin-4-yl)-5-fluoro-2-methylphenyl)-4-cyclo Use of a substantially phase-pure crystalline form of propyl-2-fluorobenzamide.
20. A method for treating a disorder ameliorated by inhibition of BTK, comprising administering to a patient in need of such treatment. The present invention provides a method for producing the N-(3-(6-amino-5-(2-(N -Methylacrylamide)ethoxy)pyrimidin-4-yl)-5-fluoro-2-methyl Substantially phase-pure crystals of (4-cyclopropyl-2-fluorobenzamide) The method comprises administering an effective amount of the compound of the formula:
21. The disorders that are ameliorated by inhibition of BTK include autoimmune disorders, inflammatory diseases, allergic diseases, and the like. Diseases, airway diseases such as asthma and chronic obstructive pulmonary disease (COPD), transplant rejection; antibodies Abnormal or undesirable lymphoid tissue production, antigen presentation, cytokine production, or lymphoid tissue formation Diseases that are difficult to treat: for example, rheumatoid arthritis, systemic juvenile idiopathic arthritis (SOJIA), gout, Pemphigus vulgaris, idiopathic thrombocytopenic purpura, systemic lupus erythematosus, multiple sclerosis, myasthenia gravis Asthenia, Sjögren's syndrome, autoimmune hemolytic anemia, antineutrophil cytoplasmic antibody (ANCA) Associated vasculitis, cryoglobulinemia, thrombotic thrombocytopenic purpura, chronic urticaria (chronic idiopathic urticaria, induced urticaria), chronic allergies (atopic dermatitis, contact dermatitis, allergy rhinitis), atherosclerosis, type 1 diabetes, type 2 diabetes, inflammatory bowel disease, ulcers Colitis, Crohn's disease, pancreatitis, glomerulonephritis, Goodpasture's syndrome, Hashimoto's thyroiditis, Reb's disease, antibody-mediated graft rejection (AMR), graft-versus-host disease, B-cell-mediated hyper Acute, acute and chronic graft rejection; thromboembolic disorders, myocardial infarction, angina, stroke , ischemic disorders, pulmonary embolism; cancers of the blood-forming organs, including, but not limited to, multiple myeloma; leukemia, Acute myeloid leukemia; chronic myeloid leukemia; lymphocytic leukemia; myeloid leukemia; non-Hodgkin's disease Lymphoma; Lymphoma; Polycythemia vera; Essential thrombocythemia; Myelofibrosis with myeloid metaplasia and Waldenstrom's disease.
9. Use according to claim 9. Preferably, the disease or condition is one of those diseases that are typically ameliorated by inhibition of BTK. The disorders include rheumatoid arthritis; chronic urticaria, preferably chronic idiopathic urticaria; Sjogren's syndrome. group, multiple sclerosis, or asthma.
22. The compound N-(3-(6-amino-5-(2-(N-methylacrylamide)ethoxy) pyrimidin-4-yl)-5-fluoro-2-methylphenyl)-4-cyclopropyl- 1. A process for preparing crystalline form A of 2-fluorobenzamide, comprising the steps of: a) reacting N-(3-(6-aminophenyl)phenylacetamide in a non-chlorinated solvent, optionally in the presence of an inorganic base; No-5-(2-(methylamino)ethoxy)pyrimidin-4-yl)-5-fluoro-2 -methylphenyl)-4-cyclopropyl-2-fluorobenzamide and acrylic anhydride reacting the substance; and b) converting the product into a solid (e.g., by anti-solvent crystallization, cooling crystallization, distillation procedures, or evaporation of the solvent); and isolating crystalline form A. The method includes:
23. The method for preparing crystalline form A according to claim 22, wherein the non-chlorinated solvent is ethyl acetate. Law.
24. 24. A method for preparing crystalline form A according to claim 22 or 23, wherein form A is isolated by distillation. 。
Citation Information
Patent Citations
Novel aminopyrimidine derivatives
JP2016538313A
